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This dissertation describes the research performed in two major areas of 
dermatopharmaceutics: in vitro transdermal permeability studies and in vivo topical 
toxicity studies" The scientific focus was on the permeability studies and thus represents 
the majority of the results presented here as well as the focus of the discussions both 
preceding and following the data. The experimental design of the permeability studies 
is congruous (unless noted) with guidelines published as a result of a Food & Drug 
Administration (FDA) and American Association of Pharmaceutical Scientists (AAPS) 
workshop on principles and practices of in vitro percutaneous penetration studies (Skelly 
et ai, 1987)" For scientific continuity, it is desirable for all researchers in this field to 
adopt these guidelines" It is equally important to adopt consistent, well-defmed 
terminology related to the field" This dissertation provides a comprehensive glossary of 
terms used in the text.. It may be beneficial to review the terms prior to reading the body 
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ABSTRACT 
_~L""_"''''''' transdermal drug delivery systems are ................... __ to delivery, passive 
diffusion, of a few substances exhibiting natural These substances are 
_ ..... _ .......... "1 highly potent agents possessing a 
as well as philicity.. These limitations are dictated by outermost layer the 
.t'<Ii'''II'·''''li''''llH''''''' corneum, which acts as a barrier.. stratum __ ........... _' ...... "' ... ...........,,11 ... .., ............. Jl"'''_o.lI~4. 
protein ....... _A .... """' .. .. The barrier strength of keratin is attributed to extensive _ .. ...,_ ....... , ..__ 
bond ........ _.t'<IJf'\ ..... ,U''' ................ ~ In order to expand spectrum of transderrnal drug candidates 
keratin barrier must be overcome .. 
Low ... .Il.l._.IL~\ ... JI. ........ weight primary aliphatic thiol compounds reduce -. ....... ,_.L.III.,.L __ Iinkages 
cystine in the keratin forming sulfhydryl-terminated units and 
thus diminishes the number cross-links between polypeptide chains.. has been 
shown to increase the permeability of the skin to a variety of drugs opening up the 
stratum corneum for facile diffusion most probably through increased 
validates the use of low molecular weight primary aliphatic thiol compounds as 
UQll,."'"'''''''''''.A. ... ,lAM4. permeation enhancers .. 
One the major requirements of any pharmaceutical applied topically is lack of 
!l'T1i"II1IT1Iro,I"lIT"Ii'lf" irritation that would _"'''' __ .... the formulation unacceptable to the user.. An 
acute non-invasive dermal toxicity study on both animals and humans has shown most 
the enhancers to be well tolerated. 
eRA ER I 
Introduction 
3 
1.1 Transdermal Drug Delivery 
Transdermal drug delivery the process administering drugs through the skin 
into the bloodstream the goal eliciting a systemic pharmacological effect. In 
contrast creams ointments which are messy and difficult apply, process 
accomplished a discreet device sometimes 1II"~T"'!:lIL_t:.l>AI"II to as a "patch" that houses the 
active ingredient and provides its controlled release~ 
relatively concentrated drug is driven by the concentration gradient the "'_",,,,JLIl 
into the systemic circulation. Although patches can be manufactured to 
effective for weeks or months, current patient acceptability is for 24 hour dosing with 
a disposable patch. 
Advantages of Transdermal Drug Delivery 
Until recently, therapy was restricted to repeated _I>JJ ... 1U ...... " ..... ,."A 
forms which are difficult to apply uniformly insure reproducible 
Transdermal drug delivery provides controlled release the active over extended 
periods time thus significantly reducing the frequency of dosing. is extremely 
valuable drugs with short half-lives, where the elimination of the inconvenience of 
frequent dosing substantially improves patient compliance. Zero-order controlled release 
also avoids fluctuations in blood levels seen with intermittent dosing.. Fluctuations into 
the are the most common cause of adverse drug reactions.. For this reason 
release important for drugs with a narrow therapeutic range .. 
administration avoids a multitude of problems encountered with 








""AA""' ........ "'_ and various 1. 
are also subjected 
remove 
termination of therapy a 
a 11. .. 11 ..... '-'"-_ 
the tightly packed £ .... _£.1,;1.""'-...... structure 
within a reasonable time (Guy 
5 
the stratum corneum 
Due to limited diffusivity, only potent drugs can be delivered 
transdermally.. To a certain extent, the total quantity of drug diffused can be increased 
by increasing size of patch; but patient limits the to about 30 cnr .. 
partitioning the of 
coated cells of protein and water of the stratum corneum demand drug possess 
both lipophilic and hydrophilic attributes for adequate penetration (Michaels 1975, 
Drugs that bind significantly to skin proteins are difficult to deliver transdermally 
(Kelly 1985) .. This effect may be overcome by designing the patch in a such a way as 
to deliver an initial priming or loading dose to saturate these binding 
....... 4.&.A .... ""'" drugs and drugs that bind the skin proteins tend to stay in the 
stratum corneum causing what has come to be known as the "reservoir effect".. The 
problems associated with this phenomenon are long lag times (time to therapeutic 
response) and continued systemic drug input after removal of dosage 
_"' ..... "',...., absorbed, some biotransformation in the skin occur $ The underlying 
layers of epidermis do show some metabolic activity albeit limited (Kermici 
Drug stability could be compromised before systemic activity occurs .. 
The application site is important. Significant differences exist in the structure and 
physicochemical properties of the stratum corneum between individuals and between skin 
In same person (Southwell 1984) .. 
Drugs and excipients may primary local irritation at the of application. 
6 
of with even slight 
problematic in population. irritation 
".n"'~l"""''''.''''''' seen clinically with early transdermal drug systems were not of a -' 
but due to sweat accumulation and ."A~"A_A 
smaller, more porous systems (Moore 1988)~ systems allow 
bacteria by-products 
been stated that more 
cannot be ..... A-1;4. ... ~ into a transde·rmal 
without the use· permeation enhancement (Pfister 1990). 
1.4 The Transdermal Delivery Site 
skin consists of two distinct but mutually dependent tissues: the avascular 
epidermis and underlying dermis. is a watery, porous, nonselective 
fluid -filled connective matrix intertwined with a dense capillary network. 
epidermis a multi-laminate structure divided into four separate 
stratum granulosuffi, stratum spinosum, and stratum germinativum. A fifth 
but is seen clearly only the (foot) palmer 
(palm) ...., ..... 1 .. JJL~ (Montagna 1974). The of epidermis, excluding the stratum 
are as the since the cells of the stratum 
corneum are metabolically """' ....... _ ... .L Figure 1 illustrates a cross section of typical skin. 
outermost the epidermis exposed to the environment is the stratum 
... "....,>ul.AJUL or horny averages about 1 0 to 20 thick and about 10 to 
flattened, dense, metabolical1 y known as 
Figure 1: Cross-sectional diagram of human skin. The 
arrows depict potential drug entry routes (Montagna 1974). 
7 
corneocytes (Holbrook 1974, Bronaugh 1982) .. They are arranged in a brick-like fashion 
and are individually surrounded by a complex lipid material. Since the cells are not 
attached to each other it is believed that the lipid material acts as a cement to hold the 
structure in place analogous to the structure of a brick wall (Schaefer 1988). About 20% 
of the stratum corneum is lipid material, about 40% is keratinized protein and 40% is 
water in normally hydrated skin (Kelly 1985, Ritschel 1988). Corneocytes contain large 
quantities of the protein keratin. 
Keratin protein exists as ordered a-helical strands embedded in a less well-ordered 
globular matrix consisting predominately of the amino acid cystine. This high cystine 
content is specific for keratin (Gershon 1972). Cystine is the only amino acid capable 
8 
of forming disulfide linkages and one of only two amino acids containing sulfur.. It 
seems the only pu1J>Ose of this amino acid is to provide structural linkages (Montagna 
1974). The functions of disulfide bonds can be categorized into providing structural 
stability, mechanical strength, and chemical stability" 
1.4.1 Structural Stability 
The primary function of disulfide cross-linking seems to be that of keeping the 
skin structure intact. Keratin fibers can undergo great elongation, up to 100% in water, 
and still exhibit full recovery, if the extensions are done under conditions that minimize 
cross-link: scission (Menefee 1977). Cross-links stabilize the a-helical structure.. When 
disulfide cross-links are reduced, the stability of the helical protein chains decreases 
(Menefee 1965). The extent of sorption of liquids is determined by cross-link density. 
Disulfide content correlates well with degree of maximum swelling (Caldwell 1970) .. 
1.4.2 Mechanical Stability 
If the disulfide bonds in keratin are progressively decreased, regular changes 
appear in most standard mechanical strength tests such as Young's modulus, torsional 
modulus, yield points, br strength, and elongation to break (Feughelman 1964, 
Crewther 1965, Chapman 1969). Those properties involving high strain are usually most 
affected by cystine levels (Menefee 1977) .. The stratum corneum provides almost totally 
the mechanical strength of the epidermis (Scheuplein 1971). 
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1.4.3 Chemical Stability 
Disulfide cross-links provide remarkable barrier properties the stratum 
corneum.. cells differentiate and migrate to the surface, they undergo extreme 
densification and cross-linking thus imparting a chemical and impenetrability 
for most all compounds even with widely differing properties (Matoltsy 1976, Tregear 
1964). 
IS well accepted that permeation through the stratum corneum is the 
rate-limiting step transdermal absorption and has been proven so over the years 
(Treherne 1956, Scheuplein Shaw 1976, Flynn 1981).. The stratum corneum 
dense and compact with diffusion mechanics similar to transport through solids.. In 
contrast, the dermis, consisting fluid filled interstices, allows for liquid-type diffusion 
accounts for a permeability increase of four orders of magnitude over the stratum 
corneum with a series of compounds with varying lipophilicity (Schueplein 
"'-" ....... ,....,.A. layers the epidermis and especially the dermis are relatively more significant 
barriers to penetration of nonpolar molecules than of polar molecules due to 
aqueous environment, but they are still insignificant compared the barrier effect of the 
stratum corneum.. These layers represent only about 4 % of the total diffusional 
resistance (Barry 1983). 
1.4.4 Variations in Permeability 
Variation between individuals has marked clinical significance. is always 
"' ... .!I.1""!!, ..... u ••• A. than intra-specimen variation (Southwell 1984).. Variations in permeability of 
human stratum corneum both from person-to-person (and within each person) has been 
1I"A~n1l"t~3i;i'1 to be influenced by a complexity of 
sex, blood supply, skin temperature; individual 
include 
'Jr' .. ,w-..,,-lL.' such stratum 
corneum turnover time, appendages, thickness, packing, number and 
density; environmental factors such mechanical stress and exposure; and 
variables such as composition (lipid, protein, and water), enzymatic and _A"" ... _A ..... 
of disulfide All of these the has yet to 
have been shown to _-IkJL",,-- of the to various solutes 
varyIng (Feldmann 1967, Anderson 1973, Montagna 1974, Kermici 
Weigand 1980, Elias 1981, Barry 1983, Southwell 1984, Walters 1986, Berardesca 
1988).. number of these variables, some of which may be insignificant relative to 
others, are discussed more detail in following sections .. 
1.4.4 .. 1 Potential Variables Which Influence Permeability 
It is important to note that these are generalized statements of which there are 
and provisos.. These variations pertain to normal, non-diseased skin" 
1.4.4.1.1 Age 
The intrinsic permeability of skin shows 
from a hours after birth to extreme old 
variation, relative to other variables, 
ultrastructure of the stratum 
corneum in a newborn is indistinguishable from that of an adult (Walters 1986) .. 
1.4.4 .. 1.2 Sex 
is no information to suggest permeability differences between the sexes" 
Any differences that may occur are insignificant relative 




The stratum corneum of blacks has the same thickness as whites but the density 
of the corneocytes and number of cell layers is significantly greater (Weigand 1980) .. 
This leads to greater barrier effect in terms of solute permeation. This difference could 
lead to specific race-oriented transdermal pharmaceutical products (Berardesca 1988). 
1.4.4.1.4 Blood Supply 
The blood supply rises up into the dermis but not the epidermis. The vessels 
penetrate to within 150-200 I'm of the skins surface (Idson 1975).. From the point of 
view of standard cellular metabolic need, the skin is vastly overperfused" Estimated 
minimum flow requirement for cellular respiration is about 0 .. 5-1 .. 0 ml tissue .. 
The mean cutaneous flow is some 20-30 times greater than this minimum maximum 
flow can be more than 100 times (Barry 1983).. The physiological reason for 
phenomenon is the use of the cutaneous vascular system as the prime regulator of total 
body temperature" In fact, human skin is so rich in blood that it can store as much as 
4 .. 5 of the total blood volume (Montagna 1974)" The skin receives 33% of the average 
cardiac output (Szycher 1986).. This immense volume and turnover rate results in no 
inter-individual differences in permeability due to blood supply and is ideal for systemic 
drug delivery via the transdermal route.. Also, for any transdermal system, it is unlikely 
































Figure 2: Cross-sectional diagram of human 
epidermis with arrows depicting the hydrophilic 
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Figure 5: Concentration vs. distance diagram of the physicochemical processes of 
transdermal drug delivery. 
The series of events of transdermal drug delivery is governed by system design, 
physicochemical principles, and physiological state. Pharmaceutical scientists have 
difficulty controlling the physiological state of the patient, cannot change the 
physicochemical laws of nature, and therefore have only their ability to improve drug 
delivery system design as their means to a pharmacologic goal. 
Specific system modifications designed to augment transdermal permeability include: 
• Increasing the thennodynamic activity of the drug in the delivery system. The 
simplest method is to increase drug concentration. If at saturation, other techniques 
• 
Ie 1: The cts of favorably altering partitioning (K)>> 
Ii ivity (D), drug solubility (S), and membrane thickness 
(h) on lag time, time to steady-state, and steady-state flux; 
(' =increase, + =decrease, O=no change) 
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The one variable that, when increased, favorably alters the three parameters of 
lag time, time to steady state, and steady state flux is diffusivity (0);> Therefore, 
permeation enhancers which have the most profound effect on the permeation profile are 
these which increase diffusivity .. 
III studying the effects of potential permeation enhancers on the stratum corneum, 
tie m.ianismof action may be revealed by measurement of the lag time (Guy 1988) .. 
Purtherinsight can be obtained by considering how the partition coefficient alters in 
.-june·~ n with the diffusional lag time. If the lag time shortens in the presence of an 
Mkancer, out the,.partition coefficient does not change, then the enhancer must have acted 
• the usivity alone.. On the other hand, if the partition coefficient increases due to 
tie enlwmeer but the lag time remains the same, then the enhancer is affecting 
~tioBiBg intotne·skin .. These deductions assume, of course, that the enhancer has no 
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Figure 6: Concentration vs. distance diagram showing the effect of increasing the 







LEVEL OF DRUG INPUT 
Figure 7: Concentration vs. distance diagram showing the effect of increasing 
tfljfusivity in the stratum corneum. 
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Figure 8: Concentration vs. distance diagram showing the effect of increasing 
partitioning into the stratum corneum. 
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Figure 9: Concentration vs. distance diagram showing the effect of decreasing the 
thickness of the stratum corneum. 
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CHAPTER IV 
Transdermal Permeation Enhancement 
51 
4.1 Introduction 
The future of transdermal delivery lies mainly in the ability to overcome its 
exisfift, limitations. The main limitation is that most compounds cannot sufficiently cross 
the stratum corneum barrier. Research efforts are now geared toward the development 
of adjuvants which promote the transdermal permeation of ·drugs.. A comprehensive 
review by this author of the U .. Sm patent status in the transdermal field revealed that of 
the -patents examined, over 40% were for permeation enhancement techniques .. 
Permeation enhancers function by altering the barrier properties of the stratum 
.ern... thereby enhancing passive permeation" The possible mechanisms of 
enhan~ent include (Francoeur 1985): 
:. alteration of the intracellular protein structure which results in increased 
diffusivity ~ 
, alteration of the affmity of the skin for the drug which changes the 
skin/vehicle partition coefficient 
• fluidization of the intercellular lipid structure which results in increased 
fiiffusivity (plasticizer effect) .. 
• extraction of lipid components which removes the lipid barrier effect .. 
• ,increased skin hydration which changes the skin/vehicle partition 
ooefficient and/or diffusivitYe 
• osmotic shear or stress which alters drug diffusivity & 
• unspecified irreversible damage to the stratum corneum" 
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It is likely that many of these agents operate by more than one mechanism.. Table 
21ists many of the permeation enhancers found in the literature (Allenby 1969, Higuchi 
197i, :Breuer 1979, Smith 1979, Southwell 1983, Nagai 1983, Zupan 1984, Francoeur 
1~35, Sate> 1988, Okabe 1989, Wong 1989). 
It is important to note that enhancers function strictly by altering the structure of 
Ike stratum corneum and opening it up to facile diffusion. In other words, enhancers are 
:lot druB carriers per se, but allow for increased mass transport~ 
Many permeation enhancers within the transdermal dosage form are also good 
solvents for drugs and increase flux by increasing thennodynamic activity through 
mcrease4 salubility. Although not true permeation enhancement by definition, this effect 
shluld De accounted for and possibly even taken advantage of.. However, the 
ma4ef1llacies of a dosage formulation should not be concealed by increasing the 
Hncentrawon in the dosage form, which may lead to precipitation or intensification of 
at toxicity .. 
The selective effect of an enhancer is the result of a tridimensional interaction 
ietween the drug, the skin, and the enhancer. Most dosage form excipients function to 
the dosage form,. Enhancers alter the target tissue and is therefore an 1tactive 
.tipient tt " 
From a practical standpoint enhancers should meet certain requirements.. They 
sieuld be systemically inert elliciting no pharmacologic effect. Their action should be 
specific to the stratum corneum, affecting no other skin layers., Involvement with other 
liVing .ssue'layers would result in a possible irritant or allergic response due to cellular 
insult.. They should act quickly and with predictable duration.. The effect should be 
2: Agents Studied As Transdermal Permeation Enhancers. 
The chemical class, a general structure, and specific example(s) 
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human hair (a "pe~mctrient .. ).Oncethe·disulfideb()Il4$~·ljr9ketlllYtheitl1foglycQlate, 
,". ::"::'\":":' ::~.'::: .. '::'< .. :.: .. ,:,": ::": ::< .".: .. :"... . :. ':"::.":".: ..... : ... : .. :: ,,: ",":':: "':.::":::; <.: .. < .. : ..... '." ...... ' .' ".". 
the lair becom~·'Iil.gileandcarl·beplaCed. in . any . deSired COt111g4ra.tion (KolafI972) ~ 
There is s~Qgsimilarifybf!tweenthe .structuteofth~skin 'andhair's ..Bothare 
,;> ......•..••.. . .•......•..•. '.', 
keralb1\H0us in' c~in'()C)sition an(t<8resubject·t(fattackby the. same ·chemicals . to nearly 
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the same degree (Barry 1972)D 
An inviolate rule of diffusion is that molecules will follow the path of least 
lesistance. In extensive studies of diffusion in polymeric matrices, the path of least 
FeSistance is determined by, among other factors, the extent of cross-linking and packing 
ef polymeric chains (Flynn 1985)$ 
The polypeptide chain of keratin is not unlike the physicochemical ultrastructure 
ef synthetic polymers.. The direct dependency of solute diffusivity in polymers on 
tress-linking and the action of thioglycolates on human keratin seeded the hypothesis that 
tilieglycfJimes could reduce the disulfide linkages in the keratin protein diminishing the 
numher of cross-links between ,polypeptide chains~, It is proposed that this weakens the 
.ratin IJ,nd allows for increased solute diffusivity in the stratwn corneum,. 
The specific reaction of thioglycolic acid \-vith disulfides, particularly cystine, the 
amID€) acid in keratin protein responsible for disulfide crosslinking, is given below (Barry 
1!J72). This reaction is reversible with an equilibrium constant near unity (Cleland 1964, 
GelSh0n 1972) 0 
~ R 
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Figure 1'." The stoichiometric reaction between the cystine amino acid linkage in keratin 
ami the primary aliphatic thiol thioglycolic acid& 
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By inductive reasoning a series of low molecular weight primary aliphatic thiol 
cempeunds was proposed as potential permeation enhancers.. These include metallic salts 
ef thioglycolic acid, esters of thioglycolic acid, thiol alcohols, and thiol amines restricted 
$0 straight chain alkanes that have at least one free sulfllydryl group on an alpha carbon .. 
These compounds theoretically should reduce cystine in a manner similar to thioglycolic 
aci4~ 
4.3 Methods of Disulfide Cleavage 
The cleavage of disulfide bridges is used extensively in biochemistry research 
Iecause ef its importance in both functional and structural studies of proteins. The three 
(N}mmeD available methods for accomplishing this cleavage are oxidation, suljitoiysis, and 
reduction, each having potential in transdermal permeation enhancement. Oxidation, 
.ih as with periormic acid, is simple but suffers from lack of reversibility as well as 
udesirable side reactions. Sulfitolysis shows difficulty in achieving complete reaction .. 
1\e4uction reactions are preferred because they occur measurably fast « 5 minutes) and 
ale free of side reactions (Fava 1957, Konigsberg 1972).. They also proceed to 
.mpleteness* (Konigsberg 1972).. Reductive disulfide bond cleavage is s:POntaneously 
nWlfsible (upon exposure to atmospheric oxygen) thus satisfying probably the most 
impertant criteria of a transdermal permeation enhancer .. 
* With proteins, the context of completeness refers to thestat.e of the native molecule~ 
Disulfide bridges holding together two or more polypeptide chaim are often accessible 
without unfolding the polypeptide chain whereas intrachain disulfide bridge8 usually are not~ 
Therefore, with in situ proteins, reduction offers complete interchain disulfide breakage. For 
cemplete reduction of all protein disulfide bonds, the polypeptide chain must be unfolded, 
exposing all the disulfide bridges, and using excess reducing agent$ Solutions .of 8M urea 
or 6M guanidine Hel are most commonly used to achieve this~ This suggests for this 
research that only interchain disulfide bonds in keratin are being cleaved" 
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4114 Penneation Enhancer Candidate Screening 
The initial criterion, based on the hypothesized mechanism of action, is the 
enhanicr must be a low molecular weight primary aliphatic thiol compound@ 
SplCitiwly, this requires the molecular structure to consist of a straight chain alkane 
limitM to about four carbons with at least one free sultbydryl group on an alpha carbon 
and a molecular weight not exceeding about 150 g/moL Final choice of enhancer 
caniites was based on availability, cost, existing toxicologic data, and physicochemical 
characteristics including known reactivity and stability_The structure of each enhancer 
testiG is given in Table 3.. A discussion of the known disulfide reducing 
capa\lHity/hiological activity and physicochemical description of each of the chosen 
enhancers is given below .. 
4.4.1 Blioglycolic acid ethyl ester 
A very limited amount of information was found on the uses of thioglycolic acid 
ethyl ester~ The methyl, ethyl, and propyl esters of thioglycolic acid have been used as 
griwth pFomoters for insects, fish and other animals (Kamata 1986),. 
11tBoglycolic acid ethyl ester has a molecular weight of 120& 17 g/mol and exists 
as a clear · uid with a strong unpleasant odors It has a boiling point of 156-158 <II C and 
a iensityof IJi>9 g/mL It is miscible in alcohol, ether, chloroform, benzene, and 




4. Sodium thioaIycolate 
Metallic salts are used extensively in OTC depilatories and incold-wavmgof hair 
(a"pmnanent~).. As a depilatory, the sodium and calcium salts are most commonly used 
in 2-4% strengths (Windholz 1976, Miller 1986).. As a cold-waving solution, the 
ammtnium sallis preferred (McCord 1946, Kolar 1972, Matsunga 1988). 
Sodium:woglyoolate has a molecular wei t of 114.11 g/mol, exists as white 
hygreuopic exystals with a slight characteristic odor .. It is soluble in water and slightly 
.lu1ril in alcohol. Synonyms include sodium mercaptoacetate" 
4.4.3 Mercap,oethanol 
The disulfide reducing reagent utilized for many years for in. vitro biochemical 
pretes researcb, was mercaptoethanol, until recently, when dithiothreitol (Dm became 
eemmerGially available. However, mercaptoethanol is still being used currently in some 
ils~, for example, as a disulfide bond reducer to aid in determination of enzyme 
stliility and suuc,ture-acttvity relationships (Bhatnagar 1989, Kirley 1990) and in specific 
iie-arKtl)1ical techniques requiring disulfide reduction (Thakur 1990) .. Mercaptoethanol 
iu alseicen used as a disulfide reducing agent to produce low molecular weight keratin 
. om raw keratin .{Kao 1 ).. Mercaptoethanol has been shown to be effective in 
iiSSlCiatiRg the intermolecular linkages of the head and tail of sperm at the inner nuclear 
. aemillDe and the nuclear chromatin junction.. The inner membrane of the nuclear 
.vell,il anchored by disulfide bonds to these nuclear proteins (Young 1983) .. 
Il .... ptootbanol has a molecular weight of 78 .. 13 g/mol and exists ruraclear 
6() 
liClluii witb:;"a strong characteristic odor.. It has a boiling point of 157-15SoC and a 
density 1143 g/m!.. It is miscible with water, alcohol, ether, and benzene .. 
SynonYlls include beta-mercaptoethanol, 2-hydroxy-l-ethanethiol, 
2-hytirox ylmercaptan, and thioglycol .. 
4.4.4 DiQliothreitol 
Di: reitel has now been widely adopted for biochemical protein research for 
its many advantages over mercaptoethanol or other thiols.. The disulfide reducing 
reaction p~Qeeeds to completion because it proceeds one step further than that seen with 
tie thi ·c acid-type reaction with the fonnation of a stable six-membered ring that 
it energe '" y favored over the mixed disulfide' formed with thioglycolicacid-type 
Mctiens '~'leland 1964, Konigsberg 1972). The redox potential of dithiothreitol (at pH 
7 and 25°~)'<is -O.33V compared to -O .. 22V for cysteine.. This results in an overall 
"Iuilibriunl~onstant of 1 for the reduction of cystine, the disulfide-forming amino acid 
it keratin, dithiothreitol. Since the redox potential for mercaptoetlianol, dimercaprol, 
'.i.,lyc01atos.,,;/and other thiols is close to that of cysteine, the arent overall 
tftuiliirium :cPnstant for the reaction is close to unity; thus a large excess of thiol is 
'rtlAluire4 f0f:::"(1)mplete reduction (Cleland 1964; Konigsberg 1972) .. , Dithiothreitol can 
fere be ,used at much lower concentrations and is capable of quantitatively reducing 
ii$Ulfides maintaining the thiols in a reduced 'state.. Dithiothreitol is more resistant 
te.air exicia'itntnan other thiols (higher stability), and has no characteristic offensive 
m~ptln 
Recent~::'~amples of the use of dithiothreitol are Dewar (1989) who used 
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iithlethreitolspecifically for its disulfide reducing capability in dopamine receptor 
affinity smdies and Shah (1989) who used dithiothreitol to determine the location of 
tisulfiEie oonds in the enzyme diamine oxidase* Matolsty (1975) solubilized about 90% 
ef epidermal keratin by using an alkaline buffer containing a reducing agent, such as 
iithiothreitol, to split disulfide bonds., Like mercaptoethanol, dithiothreitol has been 
•• wn to be effective in dissociating the intermolecular linkages of the head and tail of 
sperm at the inner nuclear membrane and the nuclear chromatin junction.. The inner 
. memirane of the nuclear envelope is anchored by disulfide bonds to these nuclear 
pceteins ~reung 1983). 
Dithiothreitol has a molecular weight of 154,,24 g/mol and a crystalline shape of 
slightly hygroscopic needles" It has a melting point of 42-43 0 C~ It is freely soluble in 
water, ethanol, acetone, ethyl acetate, chloroform and ethere 
. i,4~i.ithi0t~reitol, DL-threo-l,4-dimercapto-2,3-butanediol, 




Cysteamine has been shown to have a variety of biological effects.. It has 
nwiilpretlClive capability of normal skin by protecting, transforming, and scavenging 
-. radicals"'· (Verhey 1983, Held 1984)" Cysteamine also decreases acetaminophen 
hepa.tetGxicityby decreasing the cytochrome P-450 dependent formation of the toxic 
aClWninoph,n metabolite mercaptopurate (Miller 1986).. Dunsford and co-workers 
(1914) evaluated cysteamine as a potential inhibitor of carcinogenesis.. The data 
sUJlestid plIssible tissue-specific anti-carcinogenic properties.. Cysteamine 
ClntQsb1984)~· ... · Trier and 
CG-w:orirers (1987) and .; ~uiandco~wotk:ers(1987) iride.pendently indicated that 
cysteamine has agasttoprotective effect on ethanolinduced:gastricIll1J:cosaldamage* 
,ituitlrytissue, c 
.f rei bloed cells ~dobservedincrea.sedpetn1eability~ 
.' . 
Elysteamine 1l(i$iamQleeularweightof:17.15·:glmol··andexists 
, MD~). ···1)l,melrcat.rOI 
iiechemical rerepter bill ~gstudies(Yoshlkurti19881~ 
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148-C and: <a density of 1 .. 2385 g/mL Synonyms include 2,3-dimercapto-l-propanol, 
1,2-dithioglyrerol, British Anti-Lewisite (BAL), dicaptol, and sulfactin. 
4.4.7 MOBothioglycerol 
Mel1othioglycerol has been used tberapeutically in humans and by veterinarians 
hi a 1:5800 strength to promote wound healing (Windholz 1974),. 
MOlloiliioglycerol has a molecular weight of 108., 16 g/mol and is a yellowish 
visctlus liq1Uidwith a density of 1 .. 295 glmL It has a slightly sulfidic odor and is soluble 
in water,.:,;miscible in alcohol, and insoluble in ether.. Synonyms include 
3 .. mercapt~l,2-propanediol, alpha-thioglycerol, thioglycerol, and thioglycerin .. 
4.S TraBStlllGmal Drug Candidate Screening 
Although the objective of this research. is to develop a permeation enhancer 
. hliependentv:0f the drug used, certain limitations dictate a systematic approach in the 
<identificatitlllOf tentia! transdermal drug candidates.. Criteria for drug screening 
.' iaclu4e: 
• D"..Since percutaneous drug diffusion is a slow, concentration dependent 
procests, the drug must be pharmacologically potent in order to allow its 
fermulati0n in a suitable delivery system for application onto a limited surface 
area.;A corresponding oral dose should not exceed the double-digit mgl day 
range .. ,. Depending on the extent of drug absorption and first-pass hepatic 
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Figure 37(6) and (b): Transdennal flux and cumulative amount permeated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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cnough to permeate skin keratin and enter the systemic circulation" 
.WlQ!1n.. An obvious requirement is that no component the tnmsdermal 
I,tem should cause localized irritation or hypersensitivity.. Mild irritation may 
tably minimized with proper formulation.. Transdermal dosage form 
t19mponents should be tested for primary irritation early in the development stage .. 
• Proteins in the skin may serve as binding sites for certain drug 
molocules.. Bound drugs cannot diffuse as intended.. This also contributes to the 
Jacrvorr effect. Binding may also allow sufficient time for potential drug 
.embolism by dermal enzymatic activity .. 
• · ~ ., Transdermal delivery is initially limited by the time of drug diffusion 
time) yet once steady flux has been established, therapy can be maintained 
. iadefmitely,. Therefore this route of administration is suited, and ideally so, for 
cARmie conditions where continuous zero-order drug input is most efficient., 
• The inconvenience of frequent dosing of drugs with short 
pharmacologic half-lives is minimized with continuous tnmsdermal delivery. 
versely, drugs with long pharmacologic half-lives are inherently long lasting 
for the elimination kinetics are ca Ie of maintaining a (desired) prolonged 
dUN_en of effect. These of compounds may not benefit substantially from 
C811trolled release offe. by tnmsdermal administration .. 
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These criteria constituted the basis of choosing transdermal drug candidates from 
the standpoint of a clinically useful, marketable product~ It is important to note that the 
m04el drugs for this research were chosen initially for specific experimental reasons, 
then their clinical applicability and feasibility was evaluated.. A discussion of each drug 
utilized in relation to their experimental value and qualification in meeting the above 
criteria is given below" All information was obtained from ~~~~~~~~ 
lCastrup, Ed., I.B. Lippincott Co .. , SL Louis, MO., except for aqueous solubilities and 
oil/water partition coefficients which were experimentallydetermined~ 
4.5.1 Acetaminopnen 
Acetaminophen was chosen as a model drug because it possesses an adequate 
Mlance between hydrophilicity (aqueous solubility of 14 mg/ml) and lipophilicity 
~il/water partition coefficient of 3). This balance should provide some natural 
pmneation from which to establish a baseline for enhancement. 
Acetaminophen is a prostaglandin synthesis inhibitor (pGSI) type analgesic and 
•• -pyretic., Several factors connote transdermal delivery. Acetaminophen has a 
Jiarmacelelic half-life of 1-3 hours and a dosing frequency of every 4-6 haursm It can 
,e, used to treat chronic conditions of pain andlor fever.. Oral absorption is variable 
retJUiring fItS to 2 hours to achieve peak blood levels.. Acetaminophen is extensively 
h~patically metabolized (94 %) but not extensively protein bound" Acetaminophen bas 
amelecular weight of 151 .. 16 g/mol. The only factor prohibitive to transdermal delivery 
is*e rCNIuin~d systemic therapeutic blood level of 5-20 m,gIL .. This, is beyond the range 
achievaile with current transdermal technology. 
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4.5.2 Flul'b:iprofen 
Fluroiprofen is a lipophilic compound whose transdermal route should be via the 
Upephilicpathway.. If the thiol enhancers break the disulfide bonds of the keratinaceous 
kydrephilic;:>patbway, then it can be hypothesized that enhancement for lipophilic drugs, 
is a class, should be minimal to none.. Flurbiprofen was chosen to test this logic .. 
Flurl>iprofen is a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose activity 
nes 1 I)' upon prostaglandin synthesis inhibition.. Most NSAIDs are used for their 
a-inflammatory effects in treating chronic arthritic conditions but effective analgesic 
•• vity renier them useful for mild to moderate pain as well.. Flurbiprofen is a viable 
tIUlsaermaldrug candidate in terms of its pharmacologic half-life (5~7 hours) and 
ftlquency ofd:osing (up to 4 times a day) but its daily required oral dosage of 200-300 
(for rim,tis) would be difficult to deliver transdermally" However, Mceall 
lSABs un.dergo extensive hepatic metabolism, avoidance of the "first pass effect·· with 
tallsdermal delivery may lessen this limitation to within the realm of transdermal 
viUility.. Additionally, a lower dosage for indications such as pain, dysmenorrhea, and 
s.ium may be feasible transdermally .. Flurbiprofen, like other NSAIDs taken orally, 
can .use serious gastrointestinal toxicity such as bleeding, ulceration and perforation .. 
can occur at any time and without warning and have resulted in hospitalizations 
ani even fatal·ities~ This negatively impacts the use of the oral route.. Molecular size 
wald net preClude transdermal delivery (244,,27 g/mol) but its lipophilicity may, for 
fl.iprofen has an aqueous solubility of 0.034 mg/ml and an oil/water partition 
lcient of.. Also, all NSAIDs are highly protein bound (> 90%) which presage 
.. 1"'!..... 3 b" d" MUR proteIn ··m·· Ing. 
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mterestingly, flurbiprofen is marketed in a transdermal system in Japan by Mikasa 
Pharmaeeu,uca1s (pfister 1990) a 
4.5.3 Beuoic acid 
Beuwic acid was chosen as a model compound because is has been studied 
extensively by other researchers because of its relatively high natural skin permeation 
rate (Scheuplein 1974, Guy 1982, 1984, 1985, Cooper 1984, Bronaugh 1986, Dupuis 
1936, :Bemer 1988, Parry 1 ). The results of these researchers can thus be used 
.mparaiiv:ely to validate this research. A second reason is to elucidate the effect of the 
.ial enhaneefs on the permeation rate of a compound that naturally exhibits a relatively 
!Blh permeation rate" It also bas the advantage of being stable and an excellent U" V .. 
~semer. nzoic acid has a molecular weight of 122.12 glmol, an aqueous solubility 
.. 3~5 ms/ml and an oil/water partition coefficient of 0 .. 114_ 
Beuoic acid has no therapeutic activity as a drug per se but is used as a 
preservative in pharmaceutical preparations. 
4.5.4 Xau • e series 
A homologous series of xanthine compounds, most of which are drugs that would 
aefit frem transdermal delivery, were chosen for study in terms of changing 
Ii hilicity.. The compounds in order of decreasing aqueous solubility are: dyphylline, 
caJltJl*n, e, theophylline, and theobromine., This series of compounds was studied with one 
'f tie mer, promising enhancers--thioglycolic acid ethyl ester,. Xanthine derivatives,as 
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at class, have activity as diuretics, smooth muscle relaxants, cardiac stim ts, and 
vasodilatnrs. 
4.5.4.1 TIl ylline 
phylline is ,a xanthine derivative indicated for the chronic treatment of 
iDn»nchiaf"a,s,thma.. The main characteristic of this drug that advocates transdermal 
delivery isnits narrow therapeutic index. Therapeutic serum levels range from 10 ... 20 
jig/ml with dramatic increases in toxicity seen with levels of 20-25 Itglml. Adverse 
reactions seen in more than 75 % of the patients include nausea, vomiting, diarrhea, 
, ieadache, insomnia, and irritability.. Toxicity becomes life threatening at levels above 
",g/ml th cardiac arrhythmias, seizures, brain damage, and death.. Since the 
presence o:j:·food and food type rein/carbohydrate ratio) alters the bioavailabilityand 
aisorption pattern, controlled transdermal delivery is highly advantageous. Other factors 
also suppol1t"transdermal delivery.. Oral theophylline causes local g .. i. irritation and 
. Ulually re€lulres administration with food.. Theophylline is extensively biotransformed 
il the liver; 95 %).. Serum half ... life is variable from 3-13 hours in normal subjects .. 
uency '(Jf.,dosing varies and must be individualized for each patient. Generally 
an: every J6 hours is required. 
Thylline has a molecular weight of lS(t 17 g/mol,an aquooussolubility of 
5.\1 mg/mlandan oil/water partition coefficient of 0 .. 571.. The limiting factor of 
d"'vering theophylline transdermally is achieving a serum level of 10-20 Ilg/ml. 
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4.5.4.2 Dypbylline 
Dyphylline is a xanthine derivative whose potency is about 1/10 that of 
theophylline. Its advantage over theophylline is fewer side effects.. Its pharmacologic 
half-life is two hours thereby requiring frequent dosing but its therapeutic concentration 
is similar to theophylline (12 jlg/ml) thereby limiting its transdermal viability., 
Dyphylline is not metabolized but excreted unchanged in the urine .. Its short half-life and 
lack of metabolism is due to its relatively high aqueous solubility (120 mg/ml)" 
Dyphylline has a molecular weight of 254.25 g/mol and an oil/water partition coefficient 
of 0.111. 
4.5.4.3 Caffeine 
Caffeine is a xanthine derivative used for its CNS stimulant activity" Including 
its use in beverages, this is the most consumed drug in today's society.. Self 
administration inevitably results in "peak: and valley" effects of nervousness, 
hyperexcitement, anxiety, tachycardia, and diuresis at serum peaks and lethargy, fatigue, 
and mental dullness at serum Valleys.. Caffeine has the capacity to produce withdrawal 
symptoms upon cessation of regular consumption. Controlled zero-order drug input 
available with transdermal delivery would minimize or eliminate these effects.. Caffeine 
has a molecular weight of 194 .. 19 g/mol, an aqueous solubility of 19 mg/ml, and 
oil/water partition coefficient of 0.034" It exhipits low protein binding (15 %) and a short 
pharmacologic half-life (3.5 hours).. The limiting factor in delivering caffeine 
transdennally is achieving the required serum levels of 6-13 pg/ml .. 
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4.5.4.4 eobromine 
Theobromine is a xanthine derivative which has activity as a diuretic, smooth 
muscle relaxant, cardiac stimulant, and vasodilator, albeit less than the other xanthines .. 
It has a molecular weight of 180.17 g/mol, an aqueous solubility of 0.435 mg/ml and an 
eil/water partition coefficient of 0 .. 128.. It currently is not used in a marketed drug 




The aDjectives of this study are: 
1) To establish a system for the in vitro evaluation of transdermal drug J)errneation .. 
2) To screen model drugs based on specific experimental criteria. 
3) To characterize the transdermal kinetic and physicochemical parameters of model 
drugs. 
4) To screen thiol compounds as permeation enhancers based on specific criteria .. 
5) To determine if certain thiol compounds can be pharmaceutically used as 
transdermal permeation enhancers .. 
') To assess the in vivo acute primary toxicity of certain thiol permeation enhancers. 
5.1 mtroduction 
A diagram of the research plan is given in Figure 11. The plan was initiated by 
.. blishing and testing the in vitro assay system.. Drug/enhancer compatibility and 
lIt1ractions were evaluated to determine enhancer application method. The chosen 
1m,s' transdermal pharmacokinetic and physicochemical permeation parameters were 
6letermined with and without enhancer. Permeability coefficients were compared for 
.listical differences.. Finally, animal and human primary skin irritation effects of the 
eaiancers were assimilated.. This information was then collectively used to critically 
enluate the use of primary aliphatic thiols as transdermal permeation enhancers .. 
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5.2 Materials and Methods 
5.2.1 List of Materials 
5.2,,1,,1 Chemicals 
Acetaminophen, Ruger Chemical Co, Irvington, NY, Lot # G18804C18. 
Acetic Acid, Glacial, Fisher Scientific, Fair Lawn, NJ, Lot #896949; Lab Grade. 
Ammonium Acetate, Fisher Scientific, Fair Lawn, NJ, Lot #289756; Lab Grade" 
Ienz0ic Acid, Sigma, St. Louis, MO, Lot # 78F-0390; Cat. no. B-3250; Lab Grade, 
Caffeine, Sigma, St. Louis, MO, Lot # 127F-0395; Cat. no .. C-0750; Lab Grade. 
2,3-Dimercaptopropanol, Sigma, St. Louis, MO, Lot # 40H0803, Lab Grade" 
BL-Dithiothreitol, Sigma, S1. Louis, MO, Lot # 117F-0032, Lab Gradee 
BL-Dithiothreitol, Sigma, SL Louis, MO, Lot # 69FOO83, Lab Gradee 
:lyphylline, Sigma, St. Louis, MO, Lot # 126F-0308; Cat. nOM D-0633; Lab Grade. 
1,2-Ethanedithiol, Sigma, S1. Louis, MO, Lot # 110f-0001; Lab Grade .. 
:l!thyl Alcohol, Warner-Graham Co"' Cockeysville, MD~ ,Lot # June 20, 89; Lab Grade .. 
Flurliprofen, (U-27 , 182), Upjohn Co .. , Kalamazoo, MI, Lot # 0498F; Lab Grade. 
Methanol, Fisher Scientific, Fair Lawn, NJ, Lot #772367, HPLC grade. 
Mercaptoethanol, Pierce Chemical Company, Rockford, II, Lot # 862 16084, Lab Grade .. 
Mercaptoethanol, Sigma, St. Louis, MO, Lot # 48F-0028; Lab Grade. 
2-Mercaptoethylamine, Sigma, S1. Louis, MO, Lot # 67F-0032, Lab Grade .. 
Mlnothioglycerol, Sigma, St. Louis, MO, Lot # 47F-0755; Lab Grade .. 
Light Mineral, U .. S .. P., Lubinol~, Purepac, Elizabeth, NJ, Lot # C24A 
SMium Chloride, Fisher Scientific, Fair Lawn, NJ, Lot #714068; Lab Grade" 
SMium Phosphate, Dibasic, Heptahydrate, FisherBiotech, Fair Lawn, NJ, Lot # 885404; 




Jer Figures And Chemical Structures: 
LOTUS FREELANC.E PLUS (Version 3.01) 
Lotus Development Corporation, Cambridge, MA 
Jer Text, Figures, Tables, And Equations: 
WORDPERFECT (Version 5.1) 
Wordperfect Corporation, Orem, UT 
Por Graphs: 
SLIDEWRITE PLUS (Version 3) 
Advanced Graphics Software Inc .. , Sunnyvale, CA 
Per Chemical Structures: 
MOLECULAR PRESENTATION GRAPHICS 
Hawk Scientific Systems, Inc., Kinnelon, NJ 
Fer l)ata Manipulation And Analysis: 
LOTUS 1-2-3 (Release 2.01) 
:lotus Development Corporation, Cambridge, MA 
5.2.1.4 Equipment 
Spectrophotometer: 
Variable wavelength U .. V .. spectrophotometer .. Model 481 (pn98293) 
Millipore Corporation, Waters Chromatography Co .. , Millford, MS 
Fixed wavelength U .. VI) spectrophotometer. Model 441 
Millipore Corporation, Waters Chromatography Co .. , Millford, MS 
U"V. Diode Array Spectrophotometer. Model 5451A 
Hewlett Packard Company, Cupertino, CA .. 
Integrator: 
Control module. Model 740 
Micromeritics Instrument Corp .. , Norcross, GA 
Chroma to pac· Model C-R3A 
Shimadzu Corp .. , Kyoto, Japan 
Recorder: 
Single channel strip chart recorder .. 
Linear Instruments Corp .. , Reno, NY 
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Chw;ulat0r: 
Constant temperature water bath. Model 800. Catalog no .. 13-874-71A .. 
Fisher Scientific, Fair Lawn, NJ 
Di lion cell: 
Franz flow-through model FDC-200, 9mm. 
Crown Glass Co .. , Somerville, NJ 
Fluid delivery systems: 
Volumetric Infusion Pump. Micro 965 CA92131 (pediatric). 
lMED Corporation, San Diego, CA 
HPLC Pump. Model 750 
Micromeritics Instrument Corp .. , Norcross, GA 
Sample Injector. Model 7125 equipped with a 20J-Ll injection loop 
Rhoodyne, Cotati, CA 
HPhC column: 
Reverse-phasee Microsorb~ CI8, 5JLm particle size 
Rainin Instrument Co. ,Emryville, CA 
5.2.1.5 Supplies 
Filters: 
Millex-SV, 0 .. 5 p'm pore size, 
Millipore Corp., Bedford, MA 
Patties: 
Hill Top Research, Inc .. , Cincinnati, OR 
5.2.1.5 ADimals 
Guinea pigs: 
Athymic male nude (hairless) guinea pigs 
Charles River Co .. , Willimington, MA 
Plumas: 
Normal male and female caucasians, Charleston, SC 
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5.2.2 In Vitro Assay 
The following discussions describe not only the components and procedures of the 
in vitro assay system but also describe the rationale for each .. 
S.2.2.1 Selection and Rationale for Diffusion Cell Design 
The system is designed as a continuous flow-through type as opposed to a finite 
sampling system in an effort to automate and expedite the evaluation process. 
Continuous sampling allows continuous monitoring of the permeation profile which 
allows the visualization and elimination of extraneous interferences such as electronic 
spikes, air bubble spikes, and the like.. Sink conditions are easi.ry maintaiIled 
IOntmuous flow-through systems even with studies that accumulate large amounts of 
.lute (Bronaugh 1985).. Flow-through more closely mimics blood flow through the skin 
taking 'up and carrying away permeating compounds.. Also better mixing is obtained 
with the flow-through cell.. In a study of the permeation of a homologous series of 
p-aminebenzoates, as the series is ascended, there is a shift in diffusion controlled by the 
aembraneto one in which permeation is controlled by the aqueous diffusion layers.. It 
was apparent that the effective thickness of the aqueous boundary layer is less when the 
flew-through cell is used thereby returning control of diffusion back to the membrane 
fA,ddicks 1987). Flow-through cells are recommended in the FDA and AAPS Guidelines 
fer they tend to minimize collection problems (Skelly 1987) .. 
In a'.diffusion cell system, the total quantity of solute that can accumulate in the 
rlteptor compartment is determined by its affmity for the receptor fluid (solubility) and 
the volume of the receptor compartment. Together, this affInity and volume define the 
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Witlding capacity" of the receptor compartment (Riley 1985).. In a static system, the 
IlCeptefvolume is fiXed.. Therefore, the holding capacity can be increased only by 
eian:ing:,the relative affinity of the penetrant for the receptor fluid, which leads to 
deviations from in vivo mimicking.. However, in a flow-through system, the receptor 
velume becomes infinity large as flow rate is increased.. The holding capacity can be 
ilcreased,indefinitely by increasing the flow rate. 
J.2.2.2Seurce and Rationale r Membrane Selection 
Many in Vitro experiments are done with animal tissue. This is usually done out 
necessity rather than preference because the procurement of the appropriate viable 
h,.an tissue may be difficult or impossible.. Ideally, a product whose ultimate 
a Ii •• on is on human tissue dictates that testing and development should be on that 
Additionally, extrapolation of animal data to human biological systems is 
inherently error laden.. This is pertinently evident with transdermal permeation studies 
wtLere permeation differences between human and animal skin of 0 .. 5 to 40 fold have 
observed depending on the drug used (Bronaugh 1982, Scott 1986).. Montagna 
(1974) pointed out that no animal skin sufficiently resembles human skin to serve as a 
leural model for transdermal studies .. In general, animal skins are more permeable than 
hUlUn skin (Bond 1988, Friend 1989) .. For these reasons the use of human epidermis 
is ,referred., All in vitro experiments of this study are done with human tissue. Since 
the rate limiting barrier, the stratum corneum, consists of anucleated, metabolically 
.active oomeocytes, in vitro data has been shown to correlate well with in vivo 
permeation profiles (ldson 1975, Franz 1975, 1978, Bronaugh (I) 1982). 
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The skin must be fresh, healthy, disease-free and undamag ,especially the 
stratum corneum.. Potential sources are from cadavers or from cosmetic surgical 
procedures. Epidermis from cadavers may have a questionable history time of 
death to receiving the tissue; the most common variable being the length SInce 
death. In contrast, epidermis from plastic surgery can be obtained immediately after 
removal and utilized promptly or frozen, thereby assuring minimal cellular decay. One 
cosmetic surgery procedure that provides a sufficient quantity of epidermis is reduction 
mammoplasty B All skin used in this study was obtained from this source.. The source 
of skin is controlled with respect to anatomical site, sex, and race but not age, although 
the age was noted for each sample and limited to a maximum age of 50 years. Use of 
epidermis from one anatomical site minimizes the intra-specimen variation in 
permeability (Kermici 1977, Southwell 1984). The FDA and AAPS Guidelines 
recommend specifying the source of the skin: whether from a surgical procedure or 
excised (from cadaver) (Skelly 1987). 
Another potentially important variable minimized by use of breast epidermis 
the effect of environmental exposure on permeability" The most poignant environmental 
factor is ultra-violet radiation (UVR) (sun exposure) which normally is dismissable with 
'breast tissue. 
5.2.2.3 Receptor Medium 
The diffusant receptor medium is designed to mimic physiologic conditions. It 
consists of a sterile, pH 7 .. 4 phosphate buffered isotonic saline solution (Sorensen 
phosphate buffer)a A 0 .. 001 concentration of phenylmercuric acetate (Hadgraft 1986) 
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or a.OO5% thimerosal (Katz 1971, Bronaugh 1982) is added as a preservative .. 
Thimerosal is preferred due to a higher aqueous solubility.. The formula used is given 
ielow .. 
Monobasic Sodium Phosphate monohydrate (Fisher) ....... ,. ........... "" ... "." 3 .. 68 grams 
Dibasic Sodium Phosphate heptahydrate (Fisher) ............................. " .. ".". 28 .. 58 grams 
Sodium Chloride (Fisher) ............. &" .......... s .... " ......... " .. " .. " ... ,." ..................... " .... ,. .. " .. " 8 .. 80 grams 
Thimerosal (Sigma) ............. "' ........................................ '" .... "" .. " ......................................... " .... 0 .. 10 grams 
Sterile Water (Travenol) .. "'"" ........................................................................... " ................................ q .. s .. 
to make .... "' ........ "" ........................... ., ...................................................................................... " .. " .......... 2{)()() ml 
The solution is filtered (Millex-SV) and sonic-suctioned degassed prior to use .. 
A four week expiration date is arbitrarily assigned .. 
5.2.2.4 Transdennal Diffusion Cell Operation 
The diffusion cell is a two-chambered jacketed Franz diffusion cell (Crown Glass 
Co .. ). The cell and related components are made of inert, nonreactive materials .. 
incl\ldes all accessories such as tubing, collection chambers, etc.. This is consistent with 
the FDA and AAPS Guidelines (Skelly 1987).. Figure 12 shows a schematic illustration 
of the diffusion cell with related support equipment.. The diffusion membrane was 
sandwiched between the donor and receptor half-cells.. The receptor half-cell is 
,lass-jacketed and was maintained at 37·C via continuous circulation of water from a 
constant temperature water bath (Fisher).. A magnetic stirring bar was operated in the 
tor half-cell to minimize the hydrodynamic diffusion layer of drug underneath the 
membrane. Stirring rate was constant for all experiments.. The donor half-cell is not 
jacketed therefore the drug formulation was at room temperature except for residual heat 
transferred from direct contact with the membrane.. This is consistent with in vivo 
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ON THE PERMEATION OF ACETAMINOPHEN 
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Figure 13: Tran.sdermolfllD fl/¢l~ ~ /¥~~At?Fk'? ////??R~k //a?Iia7r 
skin in vitro with no enhancer, ethanol, and mercaptoethanol. (The 
. error bars are the standard deviation/or n=3.) 
repared and analyzed by HPLC according to the following chromatographic conditions: 
'; The mobile phase was prepared by mixing 2.0% by volume 1M acetic acid 
(Fisher), 7.5% by volume 1M ammonium acetate (Fisher), and 4.9% by volume HPLC 
e methanol (Fisher), with 85.6% by volume distilled water. The procedure utilized 
Mic~ meritics model 740 control module, a Micromeritics model 750 solvent delivery 
system, a Rheodyne model 7125 injector equipped with a 20 JLl injection loop, a 5JLm 
'nin Microsorb~ Cl8 reverse-phase column, a Waters model 441 UV detector, and a 
" 
( 
matopac~ model C-R3A integrator (Shimadzu). A 20 JLl sample was injected on the 
lumn with a constant flow rate of 1.0 mllmin. The absorption was monitored at a 
" 
wavele!lgth of 254 nm. 
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Figure 15: Regression curve of the oil/water panition coefficient vs. 
fluxfor the xanthine series of compounds (R2 = 99.4%). 
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fly accommodated by the lipid phase (e.g. steric hindrance), will display low skin 
rmea.tion despite predictions to the contrary (Michaels 1975). 
The use of mineral oil as a correlation parameter to stratum corneum partitioning 
has distinct advantages. When direct determinations are made using pieces of stratum 
corneum, the partition coefficient is complicated by several considerations. For drugs 
that are highly protein bound, it is impossible to tell to what extent partitioning is due 
t binding instead of solubility. This is indistinguishable even with analytical methods 
that directly measure each phase independently (such as scintillation counting). Bound 
m lecules do not contribute to permeation. A second problem is that experimentation 
involves soaking the stratum corneum for extended periods of time resulting in full 
hydration and extensive swelling eventually resulting in tissue maceration. This is 
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8 C o E F G H 
ENHANCER 
Figure 33: The 95 % Least Significant Difference (LSD) intervals for the permeability 
coefficient means of transdermal benzoic acid. 
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7.3.2.10 Discussion 
As originally stated in the experimental design, the purpose of studying benzoic 
acid is for comparison with the extensive work of other researchers thus serving to 
validate this research. A detailed study was recently published by Parry (1990) and most 
closely correlates with the parameters of this work. A direct comparison of the 
parameters and results of Parry's work and this work is given in Table 23. The critical 
parameter for comparison is the permeability coefficient. Parry's system resulted in a 
permeability coefficient of 0.031 ± S.D. 0.060- cm/hr as compared to 0.013 ± S.D. 
0.0011 cm/hr for this work. This is adequately equivalent considering the differences 
in the two systems. The most influential difference is most likely the donor solution 
solute concentration since, according to Fick's law, solute concentration directly 
determines permeation rate. Parry's concentration of 5 mg/ml (due to higher donor 
chamber temperature) should result, as is shown, in a higher permeation rate as 
compared to the concentration of 3.5 mg/rnl of this work. 
The second reason for studying benzoic acid was to elucidate the effect of the 
thiol enhancers on the permeation rate of a compound that naturally exhibits a relatively 
high permeation rate. Figure 32 shows the changes in permeability coefficients through 
human skin in vitro due to pre-treatment with various thiol enhancers as compared to no 
enhancer. 
Increases in permeation were seen with all of the thiol enhancers but profound 
increases were not evident. The average permeation enhancement for all of the 
enhancers was 1.7 fold. The greatest effect was by sodium thioglycolate with a 21h fold 
-This relatively large standard deviation is due to its calculation with propagation...of-errors. 
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Table 23: Comparison of the parameters and results of transdermal benzoic acid of published 














Donor Soln Temperature 
Donor Solution 
Solute Concentration 
Donor Solution Volume 
Receptor Solution 
Receptor Soln Temp. 










Human Female Human Female 
Abdominoplasty Mammoplasty 
4·C (Refrig.) -4 • C (Frozen) 
Tissue Culture 
Medium Normal Saline 
Split-thickness Split-thickness 
Side-by-side Franz 
Aqueous Saturated Aqueous Saturated 
SoIn. Supernatant Solution with Excess 
3S·C Room Temperature 
5 mg/ml 3.5 mg/ml 
3m1 Sml 
Distilled Water Isotonic pH 7.4 Buffer 
3S·C 37·C 
3ml 3ml 
0.785 cm2 4.52 em2 
0.26 em2/ml 1.5 cm2/ml 
Scintillation Counting Ultraviolet 
Finite (100 1'1 q 4 hrs Continuous 
with replacement) Flow-Through 
31 #Lm 21.5 I'm 
Human SkinlWater Mineral OilIWater 
4.8 0.114 
2.1 x 100s em2/hr 2.5 x l(T3 em2/hr 
0.031 emlhr 0.013 cm/hr 
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increase in permeation. Does this mean that for a compound with a natural high 
permeation rate, large increases in permeation may not be possible? Theophylline, a 
drug studied in this work, coincidently has a relatively similar aqueous solubility and 
oil/water partition coefficient to benzoic acid yet a non-enhanced steady-state flux of 
30-40 times less. If this high permeation rate of benzoic acid has an effect on the 
efficacy of the thiol enhancers, then the extent of enhancement between theophylline and 
benzoic acid will demonstrate these differences i.e. theophylline should show a much 
higher degree of enhancement than benzoic acid. As will be shown later, the magnitude 
of enhancement of theophylline was similar to benzoic acid thus suggesting the extent of 
enhancement by the thiol enhancer studied is due to the inherent physicochemical 
attributes of benzoic acid and not on its flux capacity. 
One-way analysis of variance shows that the variance between enhancer groups 
is greater, due to at least one enhancer group, than the variance within each group. 
Multiple range analysis using 95 % LSD intervals shows no difference between 
dimercaprol and cysteamine, no difference between cysteamine, mercaptoethanol, and 
thioglycolic acid ethyl ester, and no difference between mercaptoethanol, thioglycolic 
acid ethyl ester, and monothioglycerol. Otherwise, all other groups were 
non-homogeneous. Cochran's test for homogeneity of variance shows non-homogeneity 
of experimental error within groups. 
Thioglycolic acid ethyl ester, mercaptoethanol, and cysteamine reduced the 
diffusional lag time by 50% to 75%. Sodium thioglycolate increased the lag time by 
three fold. The cause of this phenomena is unknown at present, but the fact that the 
average lag time also increased using this enhancer with acetaminophen while no other 
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enhancer did, implies that this may be a characteristic peculiar to sodium thioglycolate. 
No significant reductions in lag time were seen with the remaining enhancers. As 
previously discussed, experimental error may obscure true differences. 
The thiol enhancers generally caused a delay in the time to reach steady-state with 
benzoic acid as compared to no enhancer. The effect varied widely. The average 
increase was 1.8 ± S.D. 1.9 hours. This delay may simply be due to the higher 
steady-state flux seen with the enhancers because the rate at which the steady-state is 
achieved appears to be similar to that of no enhancer. This implies no real change in 
solute diffusivity in the membrane. 
The results from this study suggest that for a drug molecule similar to benzoic 
acid with respect to physicochemical attributes i.e. aqueous solubility of 3.5 mglml and 
oil/water partition coefficient of 0.1, profound increases in permeation may not be 
possible using one of the thiol enhancers. 
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7.3.3 Model drug: Flurbiprofen 
7.3.3.1 Flurbiprofen with Thioglycolic Acid Ethyl F&ter 
TABLE 24: The effect of thioglycolic acid ethyl ester on the pharmacoldnetic and 
physicochemical parameters of transdermal flurbiprofen. 
The values in brackets are the standard deviations. 
Diffusional Lag Time 
(hours) 




Permeability Coefficient (P) 
(cmlhr X 10-1) 
Enhancement Ratio 
(P{FManccr}/P{No FManccr}) 
























Approximately 1.2 hours was required for flurbiprofen to diffuse through the skin 
without enhancer. The flux gradually increased reaching steady-state at almost four 
hours and averaging a zero-order drug input rate of 18.32 Ilg/cm2/hr. Using Fick's law 
(Eq. 20) and the the oil/water partition coefficient, an average apparent diffusivity of 
1.31 x 1<r' cm2/hr was calculated. The average steady-state flux of 18.32 p.g/cm2/hr 
results in an average permeability coefficient of 5.37 x 10-1 em/hr. The cumulative 
amount permeated in 24 hours was an average of 243 Ilg/cnr. 
Pre-treatment of the skin with pure thioglycolic acid ethyl ester had no effect on 
the permeability coefficient of flurbiprofen. The average steady-state flux and cumulative 
amount permeated at the end of 24 hours were correspondingly unaffected. However, 
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the average lag time and the time to steady-state were significantly reduced by 70%. 
This in itself may have therapeutic benefit. These results are represented graphically in 
Figure 34(a) and (b). 
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Figure 34(a) and (b): Transdermal flux and cumulative amount permeated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.3.2 Flurbiprofen with Sodium ThiogJycolate 
TABLE 25: The effect of sodium thioglycolate on the pharmacoldnetic and 
physicochemical parameters of transdermal flurbiprofen. 
The values in brackets are the standard deviations. 
Diffusional Lag Time 
(hours) 




Permeability Coefficient (P) 
(cmlhr X 10-1) 
Enhancement Ratio 
(p {BDbaacer}/P (No BDbaacer}) 
























Sodium thioglycolate had no effect on the permeability coefficient of flurbiprofen. 
The average lag time was also unchanged. The average time to steady-state took about 
twice as long. The average steady-state flux and cumulative amount permeated at the end 
of 24 hours were correspondingly unchanged. From these results it is evident that 
sodium thioglycolate is ineffective as a permeation enhancer for flurbiprofen using this 
technique. These results are represented graphically in Figure 35(a) and (b). 
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Figure 35(a) and (b): Transdermal flUX and cumulative amount permeated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.3.3 Flurbiprofen with Dithiothreitol 
TABLE 26: The effect of dithiothreitol on the phiJ177U2Cokinetic and physicochemical 
parameters of trarudermal flurbiprofen. 
The values in brackets are the standard deviations. 
Diffusional Lag Time 1.200 0.767 
(hours) [0.200] [0.153] 
Time to Steady-S~te 3.833 4.033 
(hours) [0.153] [0.513] 
Steady-State Flux 18.32 41.51 
Vtg/cm2/hr) [0.91] [2.05] 
Permeability Coefficient (P) 5.37 12.2 
(cmlhr X 10-1) [0.266] [0.600] 
Enhancement Ratio 2.266 
(P{Fnbancer}/P{No EDbIocer}) [0.112] 
Cumulative Amount Permeated 243.40 507.97 
Vtg/cm2/day) [19.31] [52.70] 
Dithiothreitol more than doubled the permeability coefficient of acetaminophen 
(ER=2.266). The average lag time was reduced by about one-third. The average time 
to steady-state was not significantly affected. The average steady-state flux and 
cumulative amount permeated at the end of 24 hours were correspondingly increased by 
over two fold. These results show that pre-treatment of the skin with dithiothreitol can 
double the permeability of the skin to flurbiprofen. These results are represented 
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Figure 36(a) and (b): Transdermal flux and cumulative amount permeated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.3.4 F1urbiprofen with Dimercaprol 
TABLE 27: The effect of dimercaprol on the pharmacokinetic and physicochemical 
parameters of transdermal flurbiprofen. 
The values in brackets are the standard deviations. 
IIm~f!!i&l~lm~.¢I~I!gQl.II;' 
Diffusional lag Time 1.200 0.233 
(hours) [0.200] [0.029] 




Permeability Coefficient (P) 
(cmlbr X 10-1) 
Enhancement Ratio 
(p{Enbanc«}/P{No Fnbaoca}) 




















Pre-treatment of the skin with dimercaprol had a slight negative impact on the 
permeability coefficient of flurbiprofen. However, the average lag time was significantly 
reduced by 80%. The average time to steady-state increased, but not significantly. The 
average steady-state flux and cumulative amount permeated were slightly negatively 
affected. Reason(s) for these occurrences were not readily apparent. These results are 
represented graphically in Figure 37(a) and (b). 
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Figure 37(a) and (b): Transdermal flUX and cumulative amount permeated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.3.5 Flurbiprofen with Cysteamine 
TABLE 28: The effect of cysteamine on the phannacoldnetic and physicochemical 
parameters of transdermal flurbiprofen. 
The values in brackets are the standard deviations. 
1111111~'~lllllillll~!~III~~~1 
Diffusional Lag Time 1.200 0.500 
(hours) [0.200] [0.300] 




Permeability Coefficient (P) 
(cm/hr X 10-1) 
Enhancement Ratio 
(p{FnhIDccr}/P{No &hanc«}) 




















The permeability coefficient of flurbiprofen increased by over sixty percent due 
to cysteamine (ER=1.618). The average time to steady-state was not significantly 
affected but the average lag time was reduced by 75 %. There was a corresponding sixty 
percent increase in the average steady-state flux and cumulative amount permeated at the 
end of 24 hours. These results are represented graphically in Figure 38(a) and (b). 
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Figure 38(a) and (6): Transdennal flux and cumulative amount penneated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.3.6 F1urbiprofen with Monothioglycerol 
TABLE 29: The effect ofmonothioglycerol on the phannacoldnetic and physicochemical 
parameters of transdennal flurbiprofen. 
The values in brackets are the standard deviations. 
1:!~~~l~il~~_Ii~tl[~.t.11 
Diffusional Lag Time 1.200 1.000 
(hours) [0.200] [0.200] 




Permeability Coefficient (P) 
(cmlhr X 10-1) 
Enhancement Ratio 
(p (FnIwv:er}/P{No Fnhmccr}) 




















Monothioglycerol had no significant effect on the average permeability coefficient 
of flurbiprofen. The average lag time was reduced, but not significantly. Steady-state 
was slowly reached, taking twice as long as the non-enhanced control. The average 
steady-state flux and cumulative amount permeated at the end of 24 hours were likewise 
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Figure 39(a) and (b): Transdennal fIla and cumulative amount penneated profiles of 
flurbiprofen through hunuzn skin in vitro aJterpre-treo.tment with enJumcer as compared 
to no enhancer. 
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Figure 40(a) and (b): Transdennal flux and cumulative amount penneated profiles of 
flurbiprofen through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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Figure 41: The permeability coefficients offlurbiprofen through human skin in vitro after 
pre-treatment with enhancers A through H. A=No enhancer, B=Dimercaprol, 
C=Sodium thioglycolate, D=Monothioglycerol, E=Thioglycolic acid ethyl ester, 
F=Mercaptoethanol, G=Cysteamine, H=Dithiothreitol. 
The error bars represent the standard deviation for n=3 with n-J degrees offreedom. 
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7.3.3.9 Statistical Analysis 
Between Groups 1.33 7 0.19 136.8 0.0000 
Within Groups 0.22 16 0.001 
II 
Total 1.35 23 II 
Dimercaprol 3 0.430 - 0.495 0.462 * 
No Enhancer 3 0.504 - 0.569 0.537 * 
Na Thioglycolate 3 0.511 - 0.576 0.544 * 
Monothioglycerol 3 0.522 - 0.587 0.554 * 
Thioglycolic Acid 3 0.523 - 0.588 0.556 * 
Ethyl Ester 
Mercaptoethanol 3 0.686 • 0.751 0.718 • 
Cysteamine 3 0.836 - 0.901 0.869 • 
Dithiothreitol 3 1.184 - 1.249 1.217 • 
!·.~_~I'~.i~r-.~~~.il!lIII_.ji·(1·.; 
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Figure 42: The 95 % Least Significant Difference (LSD) intervals for the penneability 
coefficient means of transdermal flurbiprofen. 
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7.3.3.10 Discussion 
Flurbiprofen was chosen as a model drug because of its lipophilic nature. It was 
hypothesized that increasing the permeability of the polar pathway would probably not 
cause increases in the permeability coefficient of lipophilic drugs. Nominal changes in 
permeation were observed with all of the thiol enhancers with the exception of 
dithiothreitol. The average permeation enhancement for all of the enhancers excluding 
dithiothreitol was 1.2 fold. The effect of dithiothreitol was a relatively modest 2.3 fold 
increase in permeation. The overall results support the above stated hypothesis. 
One-way analysis of variance shows that the variance between enhancer groups 
is greater, due to at least one enhancer group, than the variance within each group. 
Multiple range analysis using 95 % LSD intervals shows no difference between no 
enhancer, sodium thioglycolate, monothioglycerol, and thioglycolic acid ethyl ester. All 
other groups were non-homogeneous. Cochran's test for homogeneity of variance shows 
homogeneity of experimental error within groups. 
Thioglycolic acid ethyl ester, mercaptoethanol, cysteamine, and dimercaprol 
significantly reduced the diffusional lag time by an average 73 % . Dithiothreitol reduced 
the lag time by one-third. Effects of sodium thioglycolate and monothioglycerol on lag 
time were inconsequential. 
Thioglycolic acid ethyl ester decreased the time to steady-state by about 70%. 
Sodium thioglycolate and monothioglycerol approximately doubled the time to 
steady-state. The remaining enhancers had minimal effect. 
Although the thiol enhancers were never intended to enhance the permeation of 
lipophilic compounds, the ER of 2.3 with dithiothreitol warrants examination of the 
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theoretical blood levels obtainable with the use of this enhancer. Using the same system 
described with acetaminophen, blood levels after transdermal administration can be 
theoretically calculated. The flux of flurbiprofen through human skin in vitro has been 
shown by this work to be an average of 18.32 p.g/cm2/hr from a saturated aqueous 
solution. If a transdermal system was developed at this thermodynamic activity, at a 
patch size of 30 cm2, and given to a normal adult with an average clearance for 
flurbiprofen of 22.5 mlImin (Jamali 1988), the resultant plasma concentration 
theoretically should be 0.407 mg/ml (using the standard pharmacokinetic equation that 
plasma concentration is equal to the input rate divided by the clearance). Based on the 
blood level of 2-3 mg/l seen with a standard recommended dosage regimen (Smith 1989), 
therapeutic activity would not be achieved. With the enhancer dithiothreitol, the 
permeation increase of 2.3 fold gives a new flux of 41.51 p.g/cm2/hr. Using the same 
transdermal system as previously described, the enhanced plasma concentration would 
theoretically be 0.922 p.gl ml, a level near half the therapeutic goal. Further modification 
of formulation variables could probably attain systemic therapeutic efficacy. 
Surprisingly, one of the thiol enhancers exhibited a negative correlation with 
permeation enhancement. Dimercaprol reduced the permeability coefficient of 
flurbiprofen by 14%. This decrease in permeation rate was observed with replicate 
experiments and was statistically significant (p < 0.05). Specific experimentation would 
be required to ascertain the reason(s) for this phenomena. 
The results from this study suggest that for lipophilic drug molecules similar to 
flurbiprofen with respect to physicochemical attributes i.e. aqueous solubility of 0.034 
mg/ml and oil/water partition coefficient of 88, profound increases in permeation may 
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not be possible using one of the thiol enhancers. These results support the theory that 
the thiol enhancers, as a class, affect the polar keratinaceous pathway. 
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7.3.4 Xanthine Series 
7.3.4.1 DyphyJllne with Thioglycolic Acid Ethyl Ester 
TABLE 33: The effect of thioglycolic acid ethyl ester on the pharmacoldnetic and 
physicochemical parameters of transdermal dyphylline. 
The values in brackets are the standard deviations. 
~~I_i~I~~_~QI.I~ 
Diffusional Lag Time 0.800 0.733 
(hours) [0.200] [0.208] 




Permeability Coefficient (P) 
(cmlhr X 10-') 
Enhancement Ratio 
(p {Fnhattr«}/P{No Fnbancer}) 
Cumulative Amount Permeated 



















The lag time for the diffusion of dyphylline through human stratum corneum was 
an average of 0.8 hours. The flux gradually increased over the next 3-4 hours, reaching 
steady-state at an average of 4.2 hours. From this point forward, the zero-order drug 
input rate was an average of 0.197 pg/cm2/hr. ·An average apparent diffusivity of 3.18 
X 10-7 cm2/hr was calculated from Fick's law (Eq. 20) and the oil/water partition 
coefficient. The average steady-state flux of 0.197 pg/cm2/hr results in an average 
permeability coefficient of 1.64 X 10-' em/hr. The cumulative amount permeated in 24 
hours was an average of 2.640 pg/cm2. 
Thioglycolic acid ethyl ester significantly increased the permeability coefficient 
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of dyphylline by 4th fold (ER=4.567). The average lag time was reduced, but not 
significantly. The time to steady-state was significantly reduced by about half to an 
average of 2 hours. The average steady-state flux and cumulative amount permeated at 
the end of 24 hours were correspondingly increased by 4112 fold. The results show 
conclusively that the permeability of the skin to dyphylline can be significantly increased 
by pre-treatment of the skin with thioglycolic acid ethyl ester. These results are 
represented graphically in Figure 43(a) and (b). 
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Figure 43(a) and (b): Transdennal flUX and cumulative amount permeated profiles of 
dyphylline through human skin in vitro after pre-treatment with enhancer as compared 
to no enhancer. 
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7.3.4.2 Caffeine with Thioglycollc Acid Ethyl Ester 
TABLE 34: The effect of thioglycolic acid ethyl ester on the pharmacokinetic and 
physicochemical parameters of transdennal caffeine. 
The values in brackets are the standard deviations. 
Diffusional Lag Time 
(hours) 
Time to Steady-State 
(hours) 
Steady-State Flux 
(p.gl cm2 Ihr) 
Permeability Coefficient (P) 
(cmlhr X 1 O~) 
Enhancement Ratio 
(p {Fnhancer}/P {No EDbancer}) 
























The flux of caffeine through human stratum corneum (no enhancer) exhibited an 
average diffusional lag time of approximately I1h hours. Steady-state was reached at an 
average of 2.8 hours leveling off at an average drug input rate of 0.084 ,.,.g/ cm2/br. This 
results in an average apparent calculated diffusivity of 7.92 X 10-7 cm2/hr (using the 
oil/water partition coefficient) and an average permeability coefficient of 4.50 X 10-' 
em/hr. The cumulative amount permeated in 24 hours was an average of 0.893 ,.,.g/cnr. 
Thioglycolic acid ethyl ester significantly increased the permeability coefficient 
of caffeine by almost three fold (ER=2.759). The time to steady-state was unaffected. 
However the average lag time was reduced by 40 %. There was a corresponding increase 
in the average steady-state flux and cumulative amount permeated at the end of 24 hours 
by almost three fold. The results show conclusively that the permeability of the skin to 
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caffeine can be significantly increased by pre-treatment of the skin with thioglycolic acid 
ethyl ester. These results are represented graphically in Figure 44(a) and (b). 
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Figure 44(a) and (b): Transdermal flUX and cumulative amount permeated profiles of caffeine 
through hwnan skin in vitro after pre-treatment with enhancer as compared to no enhancer. 
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Pre-treatment of the skin with thioglycolic acid ethyl ester results in a slightly increased 
permeability coefficient of theophylline. These results are represented graphically in 
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Figure 45(a) and (b): Transdermaljlux and cumulative amount permeated profiles of theophylline 
through human skin in vitro after pre-treatment with enhancer as compared to no enhancer. 
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7.3.4.4 Theobromine with Tbioglycolic Acid Ethyl Ester 
TABLE 36: The effect of thioglycolic acid ethyl ester on the pharmacokinetic and 
physicochemical parameters of transdermal theobromine. 
The values in brackets are the standard deviations. 
1< 
. , ... "._. '.',," '.',' - .-"'-
I I· •.. .iil :::?OataTab.le» ...... No Enhancer: .20%· Erihancer 
Diffusional Lag Time 0.633 0.500 
(hours) [0.252] [0.200] 
Time to Steady-State 4.067 1.567 
(hours) [0.404] [0.252] 
Steady-State Flux 0.323 0.338 
(jLg/cm2/hr) [0.021] [0.052] 
Permeability Coefficient (P) 7.43 7.78 
(cm/hr X 104 ) [0.483] [1.18] 
Enhancement Ratio 1.046 
(p{Eobancer}/P{No Enb8Dcer}) [0.091] 
Cumulative Amount Permeated 5.135 5.617 
(p.g/cm2/day) [0.430] [1.241] 
Without the effect of any enhancer, theobromine took an average of 0.633 
hours to diffuse through human skin in vitro. A steady-state permeation rate of 0.323 
pg/cm2/hr was reached at about four hours. An average apparent diffusivity of 1.30 X 
10-4 cm2/hr was calculated using Eq.20 and the oil/water partition coefficient. An 
average permeability coefficient of 7.43 X 10-4 cm/hr was calculated using the measured 
steady-state flux. The cumulative amount permeated in 24 hours was an average of 
5.135 jLg/cm2. 
Thioglycolic acid ethyl ester did not significantly change the permeation rate of 
theobromine (ER = 1.046) or the average lag time. However the average time to 
steady-state was significantly decreased by 60 %. Insignificant change in the permeability 
results in insignificant change in the average steady-state flux and cumulative amount 
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permeated at the end of 24 hours. The results show that the permeability of the skin to 
theobromine was not increased by pre-treatment of the skin with thioglycolic acid ethyl 
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HUnAN SUBJECTS 
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anticipated nunber, ~ranges. ~. ethnic background. and !,.~alth status. 
Identify the criteria for inclusion or exclusion. Explain the rationale for 
the use of special classes of subjects. such as fetuses I pregnant wor..en. 
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likely to be vulnerable. espeCially those whose ability to give voluntary 
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III. Attach a lav description of the proposed research (approximately 500 words). 
This description r.1Ust be written so the average individual outside of the 
r.tedi ca 1 com.~n i ty can understand the study. 
IV. Attach original informed consent(s} to be used. f1USC Informed Consent Cuide 
~ust be followed for accepted foroat. 
v. Attach a conplete research plan or clinical protocol for All applications. 
, 
VI. If any hur.tan research aspects of the study are to be conducted at the VAne, 
attach the original inforned consent(s) to be used and the VAr1C Suppler.1ent. 
VA11C Inforoed Consent Guide nust be followed for accepted fomat. 
VII. Give specific location(s) and/or facilities where hunan research aspects of 
this protocol are being conducted (i.e. institution, building, rooms, etc.): 
M.U.S.C. COLLEGE OF PHARMACY, ROOM QE 319 
VIII.Wi11 subjects .receive r.lonetary coopensation for participation? 
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I understand that 'approval of this research involving human subjects is 
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adverse effect or research related injuries which night occur in relation to 
. the hunan experir.lentation. 1 have read and conply with IRS reporting guide-
lines published in Reflections (Septenber 1984). 
2. To submit in writing for prior IRS approval any alterations to the plan of 
hunan research. 
3. To subr.tit tinely continuing review reports of this research as requested by 
the IRS. 
4. To r.1aintain copies of all pertinent infornation related to the research 
activities in this project. including copies of inforned consent agreer.tents 
obtained fro~ participants. 
5. To notify the IRS lr.r.tediately upon terr.1ination of this project. and/or the 
departure of the principal investigator fro~ this Institution and the project. 
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ANSWERS TO aRB> APPENDIX A 
Section IT. Human Subjects. 
No. I.' The number of volunteers are expected to be 10-30 with an age range of 20-30 
years, not limited to sex, with a caucasian ethnic background. The subjects' health must 
be normal (as determined by subjective questioning) specifically with no known or 
observed skin rash, eczema, irritation, excessive dryness, known hypersensitivity to 
topically applied substances, lack of epidermal intactness, or the like. 
No.2: No specimens or samples of any sort will be taken. Data will consist of 
documentation of gross macroscopic changes to the epidermis evident upon visual 
observation and consist of erythema, edema, and generalized primary irritation. Data 
will be obtained specifically for research purposes. 
No.3.' Subjects will be recruited from a group personally known by the Investigator 
and chosen by him based on their understanding of the study, character, willingness, 
cooperativity, and ability to follow protocol. Consent will be documented via an 
Informed Consent Agreement describing the study procedure and potential risks and 
hazards. 
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No.4: Potential risks include possible transient localized physical discomfort at the site 
of application. The discomfort may take the form of cold or cool sensations, warm or 
burning sensations, tingling, prickly, or itching sensations. These symptoms are 
expected to be mild in nature and transient. No psychological, social, legal, or other 
risks are expected to occur. There are no alternative treatments that may be 
advantageous to the subject. 
No.5: The subjects will have immediate access to and freedom at their own desire to 
wash the application site with soap and water at any time during the study, thereby 
terminating any potential or realized risks. There is no risk to confidentiality. 
No.6.' The risks described above are expected to be localized, mild, and transient. 
These risks are relatively reasonable in comparison to the knowledge gained on the 
inherent irritation potential of the compounds to be tested. The benefits gained from this 
study will determine which compounds can be further studied as components in 
formulations of pharmaceutical products designed to be administered through the skin. 
This method of drug administration is called controlled transdermal drug delivery and for 
many drugs provides a less toxic, more effective, and safer method of delivery. 
Transdermal drug delivery provides zero-order controlled delivery of the active agent 
over an extended period of time significantly reducing the frequency of dosing. This is 
extremely valuable for drugs with short half-lives, where the elimination of the 
inconvenience of frequent dosing substantially improves patient compliance. Zero-order 
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controlled release also avoids fluctuations in blood levels seen with intermittent dosing. 
Fluctuations into the toxic level are the most common cause of adverse drug reactions. 
For this reason controlled release is important for drugs with a narrow therapeutic range. 
Transdermal administration avoids a multitude of problems encountered with many drugs 
administered orally. Poor or uneven oral absorption will cause undesirable blood level 
fluctuations, such as that seen with the extent of food intake and various g.L transit 
times. The drastic changes in pH along the g.i. tract adversely affect many drugs, such 
as degradation by stomach acid or acid-catalyzed hydrolysis in aqueous media. Orally 
administered drugs are also subjected to a "first pass effect" in the liver which can 
dramatically metabolize the drug thus reducing drug effectiveness. Since extensive 
metabolism is diminished, an equivalent therapeutic effect can be elicited with a lower 
total daily dose when given transdennally. In addition, the time available for drug 
absorption is limited and controlled by g.i. transit time. All these problems are 
eliminated with transdermal drug delivery. Lastly, once a drug is swallowed (or 
injected) it is very difficult to remove in the event of toxicity or adverse reactions. In 
comparison, termination of therapy of a transdermal system is accomplished swiftly by 
simply removing the patch. 
Transdermal drug delivery systems cannot be developed until the components of 
the system have been shown to be non-irritating, thus demonstrating the necessity of this 
study. 
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Section m. Lay Description. 
The purpose of this study is to evaluate the potential toxicity of a select group of 
a specific class of chemical substances applied to the skin. Toxicity can manifest itself 
in the form of erythema (redness), edema (swelling), or irritation (coldness, burning, 
itching, etc.). In order to limit the overall potential risks, the substance is applied in a 
minute amount (one drop) and that area is closely observed for changes described above. 
If the substance is too discomforting to the subject, it can be washed quickly and 
thoroughly with soap and water. 
The knowledge gained from this study will determine which compounds can be 
further studied as components in formulations of pharmaceutical products designed to be 
administered through the skin. This method of drug administration is called controlled 
transdermal drug delivery and for many drugs, provides a less toxic, more effective, and 
safer method of delivery. Transdermal drug delivery provides controlled release of the 
active agent over extended periods of time significantly reducing the frequency of dosing. 
This is extremely valuable for drugs with short half-lives, where the elimination of the 
inconvenience of frequent dosing substantially improves patient compliance. Controlled 
drug input also avoids fluctuations in blood levels seen with intermittent dosing. 
Fluctuations into the toxic level are the most common cause of adverse drug reactions. 
For this reason controlled release is important for drugs with a narrow therapeutic range. 
Transdermal administration avoids a multitude of problems encountered with many drugs 
administered orally_ Poor or uneven oral absorption will cause undesirable blood level 
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fluctuations, such as that seen with the extent of food intake and various g.i. transit 
times. The drastic changes in pH along the g.i. tract adversely affect many drugs, such 
as degradation by stomach acid. Orally administered drugs are also subjected to a "first 
pass effect" in the liver which can dramatically metabolize the drug thus reducing drug 
effectiveness. Since extensive metabolism is diminished, an equivalent therapeutic effect 
can be elicited with a lower total daily dose when given transdermally. In addition, the 
time available for drug absorption is limited and controlled by g.i. transit time. All these 
problems are eliminated with transdermal drug delivery. Lastly, once a drug is 
swallowed (or injected) it is very difficult to remove in the event of toxicity or adverse 
reactions. In comparison, termination of therapy of a transdermal system is 
accomplished swiftly by simply removing the patch. 
If the compounds of interest prove to be non-irritating, they can be further tested 
as permeation enhancers to deliver drugs through the skin thereby taking advantage of 
the transdermal route of administration. 
Section IV. Informed Consent. 
A proposed informed consent is provided in the following five pages. 
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MEDICAL UNIVERSITY OF SOUTH CAROLINA 
INFORMED CONSENT AGREEMENT 
I, , do hereby consent to participate in a study conducted by 
Robert M. Bennett for the purpose of observing the toxicity and irritation of various 
chemical substances applied to my skin surface. Mr. Bennett has explained orally to me, 
as described below, and I fully understand the following: 
A. PROCEDURES: I will be subjected to exposure to the intact epidermis of the 
forearm a volume of 0.01 ml. (one drop) or less with one or more of the following 
compounds: 









Total area of exposure should not exceed one square centimeter. No rubbing or touching 
of the application site will be done; the compounds will be allowed to spread and dry on 
their own. No one area will be tested twice and if a second study is deemed necessary, 
it will not commence until all skin areas have returned to normal. No medication, 
anesthetics, or tranquilizers will be used. No injections will be made. No compensation 
is offered. 
B. DURATION: Application will take approximately 15 minutes. Physiological 
parameters to be measured at 0,1,2,24,48 and 72 hours are edema, erythema, irritation, 
and irritability .. Observation will be made at these times. I will avoid touching, rubbing, 
or scratching the application area. I will allow no other compounds or chemicals (except 
water) to come into contact with the application area. I will avoid washing of the 
application area for 48 hours (unless too discomforting). I will avoid prolonged sun 
exposure of the application area. 
(see Pa&e 2) 
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(pa&e 2) 
c. possmLE DISCOMFORT AND/OR RISKS; Toxicity can manifest itself in the 
form of erythema (redness), edema (swelling), or irritation (coldness, burning, itching, 
etc.). In order to limit the overall potential risks, the substance is applied in a minute 
amount (one drop) and that area closely observed for changes described above. If the 
substance is too discomforting I can wash my arm quickly and thoroughly with soap and 
water that will be readily available to me. 
HAZARD POTENTIAUKNQWN TOXICITY INFORMATION 
1. 1hioglycoJates (Ihioglycolic acid ethyl ester and Sodium thioglycolate) 
Thioglycolates have had extensive and widespread topical use for many years as 
solutions for permanent waving of hair. Thioglycolic free acid (not used in the study) 
is a primary skin irritant but thioglycolate derivatives show no such irritations after 
contact periods from four to 96 hours. Sensitization tests of 162 persons showed no 
allergenic responses. The allergenic properties of thioglycolic acid and thioglycolates as 
measured by repeated patch tests were appraised as low or non-existent. Beauticians, 
who are constantly exposed to thioglycolates in their work, may show a positive response 
for contact dermatitis. 
2. Cysteamine 
Cysteamine has been shown to have the ability to protect tissue from damage to 
radiation exposure. Cysteamine also decreases liver toxicity caused by acetaminophen 
(Tylenol~) overdosage. Cysteamine injected into the body has been shown to cause 
duodenal ulcers, yet it also has been shown to protect the stomach from damage caused 
by drinking alcohol. None of these actions are anticipated due to the minimal topical 
exposure employed in this study. Cysteamine does not cause hypersensitivity when tested 
in animals. 
3. Mercaptoethanol 
Undiluted 2-mercaptoethanol is mild to moderately irritating on topical application 
to normal skin of rabbits but this effect is short-lived. 
4. Dimercaprol 
Dimercaprol is marketed in the U.S. and abroad as an injectable indicated for the 
treatment of arsenic, gold, and mercury poisoning. On the skin of man or animals, 
dimercaprol causes localized erythema and edema but no tissue damage or blistering. 
Some sensitization has been reported in humans. 





Dithiothreitol has been used to reverse acetaminophen (Tylenol-) liver damage 
caused by overdosage. In a study on the ability of dithiothreitol, L-Cysteine, and 
N-Acetylcysteine (currently marketed as Mucomyst'l by Mead-Iohnson Pharmaceuticals 
for bronchopulmonary diseases and complications) to break up excess mucous in the 
lungs, dithiothreitol was most effective and had the least irritant effect. Skin soaked in 
dithioerythritol (an isomer) solution for six hours showed no damage to skin components. 
6. Monothioglycerol 
Monothioglycerol has been used in veterinary medicine to promote wound 
healing. Injections into hamsters caused temporary sterility. Monothioglycerol is four 
to six times less toxic than dimercaprol. When applied to rabbit skin six days a week 
for two months, no gross abnormalities were found upon autopsy with the exception of 
locaHred tissue damage at the site of application and mild enlargement of the thyroid 
gland. 
General Statements: 
No reports of anaphylaxis were found in the literature on any of the above stated 
compounds. Some of these compounds have not been tested for allergenicity in humans. 
There is a possibility, as with all substances, of an allergic reaction. 
Many of these compounds are of a chemical class that may produce an unpleasant odor. 
Excessive exposure to the eyes of the vapors of some of these compounds may be 
irritating and produce heavy tearing. 
References are available upon request. 
D. POSSmLE BENEFITS: The knowledge'gained from this study will determine which 
compounds can be further studied as components in formulations of pharmaceutical 
products ultimately designed to benefit mankind by allowing the administration of drugs 
by a less toxic, more effective, and safer method. 
E. ALTERNATIVE METHODS: There are no alternative methods of obtaining this 
information. 
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Robert M, Bennett (803-792-8430) has agreed to answer any inquiries that I may have 
concerning the procedures and has informed me that I may also contact the Medical 
University of South Carolina Institutional Review Board for Human Research 
(803-792-4148) directly concerning the research study and research subjects' rights. This 
Board administers the agreement with the United States Department of Health and Human 
Services/Office for Protection (OPRR) covering the protection of human subjects 
(#M-I012). 
I understand that in the event of any injury resulting from the research procedures to the 
participant, reasonable medical treatment not otherwise covered by third party payments 
will be available free through the Medical University; financial compensation is not 
available for medical treatment elsewhere, loss of work, or other expenses. I may 
contact the Medical University of South Carolina Hospital Director (803-792-3932) 
concerning medical treatment. 
I understand that the participant's records of participation in this study are not accessible 
to the general public and confidentiality will be maintained. Information that may be 
gained from this study will be used only for research and educational purposes. 
Information may be published with permission of the principal investigator in medical 
journals, but the participant's identity will not be revealed. However, identifying 
information will be available to monitors from the M.U.S.C. IRB for Human Research, 
and the u.s. Food and Drug Administration. 
It is understood that participation is totally voluntary, and I may choose not to 
participate. I also understand that I am free to withdraw my consent and discontinue 
participation at any time .. Discontinuation will in no way jeopardize the participant's 
ability to receive treatment now or in the future at this Institution. 
I can attest beyond reasonable doubt that I am not pregnant nor breast feeding. 
I understand that no record of my participation or discontinuation will be a part of my 
academic record of this Institution. Also, my participation or discontinuation will not 
constitute an element of my academic performance .. 
I understand that any new information that is developed during the course of this study 
will be made available to me. 
(See Pa~e 5) 
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Cb.&e 5) 
I will receive a copy of this informed consent after it has been read, understood, and 
signed. 
Investigator Obtaining Consent 
Witness 
Date of Consent 
Signature of Participant 
Witness 
Signature of Legal Guardian 
(if applicable) 
(Consent form reviewed and approved by M.U.S.C. IRB for Human Research:S/1519Q) 
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Section V. Experimental Protocol. 
In partial fulfillment of the Ph.D. degree the following study is required. 
Dennal Toxicity Study of Thiol Compounds 
2. RESEARCH PLAN 
A. Specific Aim 
The objective of this study is to determine the irritation potential of a select group 
of a specific chemical class of substances applied topically to normal intact skin. The 
broad, long term objective is to isolate specific chemical substances that can be clinically 
used as absorption promoters or enhancers for topically applied drugs. 
B. Background and Significance 
Current topical drug delivery systems are limited to substances exhibiting natural 
skin penetration through passive diffusion. These substances are low molecular weight, 
highly potent agents possessing a certain degree of hydrophilicity as well as lipophilicity. 
These limitations are dictated by the outermost layer of the skin, known as the stratum 
corneum, which acts as a barrier. The stratum corneum consists mostly of the protein 
keratin. The barrier strength of keratin is attributed to its extensive disulfide bond 
cross-linking. To expand the spectrum of topical drug candidates this keratin barrier 
must be overcome. Thioglycolates react with the disulfide linkages of cystine units in 
the keratin protein forming sulfhydryl-terminated cysteine units and diminishes the 
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number of cross links between polypeptide chains. It has been shown in vitro that this 
weakens the keratin and increases its permeability by opening up the stratum corneum 
for facile diffusion of drug molecules that previously could not pass or could do so only 
minimally. The overall research effort focuses on the use of thioglycolates and other low 
molecular weight primary aliphatic thiol compounds as permeation enhancers or 
absorption promoters. One of the requirements of a permeation enhancer is that it be 
relatively non-toxic i. e. non-irritating to the skin.. This study is designed to evaluate the 
acute topical irritation potential of minute quantities of the proposed permeation 
enhancers. This information is essential in the overall evaluation of this research effort 
in the field of dermatopharmaceutics. 
C. Preliminary Studies 
Preliminary studies were completed on hairless guinea pigs according to the 
following protocol submitted to the M.U.S.C. Animal Review Committee (ARC) .. 
Title: Acute Non-invasive Dermal Toxicity Study 
This study will be in accordance with the method of Draize (1) et 
al, Specifically, two male nude guinea pigs (Charles River) approximately 
400-500 grams in weight and 30-50 days old (mature) will be used for 
exposure to the intact epidermis of the back area for a 24 hour period (or 
less) with one or more of the following compounds: 
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Ethanol (positive control) 
Normal saline (control) 
M,U,S.C. 
Compounds will be placed applied directly or in a gauze circular patch of 
19-25mm diameter. Total area of exposure will not exceed 10 square 
centimeters. Physiological parameters to be measured at 0,1,2,24,48 and 
72 hours are edema, erythema, irritation, and irritability. No one area 
will be tested twice and a if a second study is deemed necessary, it will 
not commence until all skin areas have returned to normal. No injections 
will be made. No medication, anesthetics, or tranquilizers will be used. 
Veterinary care, food, and housing will be provided by the Department of 
Laboratory Animal Resources (DLAR). 
(End of study protocol) 
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RESULTS OF ANIMAL STUDIES: 
Irritation reactions were judged by visual observation. Sensation or sensitivity 
was determined by the behavior of the animal. Draize numbers are toxicity ratings 
according to the method of Draize et al, (1944). 
IMMEDIATE PRIMARY REACI10N after application of one drop of test substance 
applied undiluted, as ethanolic, or aqueous solutions. Results are expressed as observed 












1 ()() % No reaction! No sensation 
100% At 15 min. blanching with red border. 
Very mild. (Draize AI). 
20% No reaction! No sensation 
100% At 45 min. erythema (Draize A2). 
100% At 6 hr. erythema (Draize A2), 
Slight sensation. 
0.25% No reaction! No sensation 
10% No reaction! No sensation 
10% No reaction! No sensation 
100% No reaction! No sensation 
ONE HOUR PRIMARY REACI70N after application of test substance for one hour using 
a 19 mm (0.2 ml capacity) Hill Top(l gauze patch. Results are expressed as observed 
irritation and sensitivity upon removal of patch. 
HR# 3893-R M.U.S.C. 









100% Slight drying of skin. 
100% Blanching. 
100% Erythema (Draize A2). 
100% Blanching. 
0.25% No reaction! No sensation 
10% No reaction! No sensation 
10% No reaction! No sensation 
24 HOUR PRIMARY REACI'lON after application of test substance for 24 hours using 
a 19 mm (0.2 ml capacity) Hill Top· gauze patch. Results are expressed as observed 
irritation and sensitivity upon removal of patch . 










100% Dry skin. 
20% Moderate erythema (Draize A3). 
Peeled stratum corneum. 
10% No reaction/ No sensation 
0.25 % Dry skin. 
100% Blistering. Blanching. Capillary breakage. 
Scarring. Erythema (Draize A4). 
Sat.Solo Slight blistering. Erythema (Draize A3). 
Capillary breakage. 
100% Erythema (Draize A2). 
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Reference: 
Draize, I.H., G. Woodard, H.O, Calvery, "Methods For The Study of Irritation and 
Toxicity of Substances Applied Topically to the Skin and Mucous Membranes". The 
Iournal of Pharrnacolo&y and Experimental Therapeutics. 82; 377-390, 1944. 
Discussion.' 
Toxicity manifestations of concern to this application are those seen with 
IMMEDIATE PRIMARY REACI10N. If toxicity was observed, it consisted of color 
changes only. Only one compound (mercaptoethanol) had significant erythema (Draize 
A2 = Well defined erythema). Thioglycolic acid ethyl ester indicated blanching with 
an erythematous border (Draize Al = Very slight erythema that is barely perceptible). 
Most compounds showed no reaction or sensation. 
Toxicity seen with ONE HOUR PRIMARY REACI70N was minimal. Maximum 
toxicity was seen with mercaptoethanol and consisted only of erythema not exceeding a 
rating of Draize A2. 
(end of animal study) 
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D. Etperimenral Design and Methods 
This study is designed to evaluate specific low molecular weight primary aliphatic 
thiols (listed below) applied topically to the forearm of normal adult non-pregnant, 
non-breast feeding volunteers, The number of volunteers is expected to be 10 to 30 with 
an age range of 20-30 years, not limited to sex, with a caucasian ethnic background. 
The subjects' health must be normal (as determined by subjective questioning) 
specifically with no known or observed skin rash, eczema, irritation, excessive dryness, 
hypersensitivity to topically applied substances, lack of epidermal intactness, or the like. 
The intact epidermis of the forearm will be exposed to a volume of 0.01 ml (one drop) 
or less (applied with a standard TB syringe or micropipet) of one or more of the 
following compounds: 







Ethanol (positive control) 
Normal saline (control) 
All subjects may receive any or all test compounds. Total area of exposure 
should approximate but not exceed one square centimeter. No rubbing or touching of 
the site will be done upon application; the compounds will be allowed to spread and dry 
on their own. No one skin area will be tested twice and a if a second study is deemed 
necessary, it will not commence until all skin areas have returned to normal. No 
medication, anesthetics, or tranquilizers will be used. No injections will be made. No 
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compensation is offered. Volunteers will be required to read, understand, and sign an 
informed consent form. 
The results of this study will be evaluated in accordance with the method of 
Draize et al (1944), Physiological parameters to be observed at 0,1,2,24,48 and 72 
hours after application are edema, erythema, irritation, and irritability. Subjects are 
requested to avoid touching, rubbing, or scratching the application area and to allow no 
other compounds or chemicals (except water) to come into contact with the application 
area. Subjects are also requested to avoid washing of the application area for 48 hours 
(unless too discomforting) and to avoid prolonged sun exposure of the application area. 
Only gross macroscopic changes will visually observed; no cellular or tissue components 
or specimens will be taken. 
HA~PO~/KNOWNTO~CITYThWORMATION 
1. Thioglycolates (Thioglycolic acid ethyl ester and Sodium thioglycolate) 
McCord (1946), in an exhaustive paper on thioglycolates and their use as 
solutions for permanent waving of hair, conducted tests with thioglycolic acid and other 
thioglycolates. The tests included patch tests for primary skin irritations and tests for 
allergic sensitizations. The results show that thioglycolic acid (not used in the study) is 
a primary skin irritant at relatively low concentrations (approximately 2.8%). Sodium 
thioglycolate (based on 3.52 % thioglycolic acid) showed no positive results after contact 
periods from four to 96 hours, nor did sodium thioglycolate (based on 4.6% thioglycolic 
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acid) show positive results under 24 hours, but longer exposures showed occasional 
positive responses. Thioglycolates in cream form up to 7.13 % induced no positive 
responses from four, six, and nine hour contact periods, however results from longer 
periods are shown in Table I. 
Table I 
Results from Patch Tests 7.3% Sodium Thioglycolate 
(Cream Form), Prolonged Exposure 
(Adapted from McCord 1946) 
Number Contact Time(br) No, Pos. Percent 
182 24 16 8.0 
51 48 7 13.7 
14 72 2 14.3 
12 96 7 58.3 
Individuals may become sensitive to almost any substance with most compounds 
inherently possessing various degrees of allergenicity. A few select compounds have a 
proven capacity to establish a state of allergic sensitivity. McCord's (1946) sensitization 
tests of 162 persons showed no positive responses to thioglycolates in the absence of a 
like initial response. The allergenic properties of thioglycolic acid and thioglycolates as 
measured by repeated patch tests were appraised as low or non-existent 
An extensive skin sensitization study by Voss (1958) concluded that thioglycolic 
acid was devoid of significant allergenic activity in tests on 60 subjects. 
In a case report by Storrs (1984), eight hairdressers and four clients were found 
to be allergic to glycerol monothioglycolate (not used in this study) in "acid" permanent 
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waves. He reports that in contrast, ammonium thioglycolate and other thioglycolates 
have been used since 1943 in cold "a1kaline" permanent waves both in homes and salons 
with no clearly documented cases of contact allergy. 
In a report by Wickett (1987), he states that permanent waves "generally rely on 
high alkalinity to break the bonds and reform them with acid. Problems with permanent 
waving are usually due to over-treatment or under treatment of the hair, rather than 
allergy or irritation. Straighteners can be irritating because o/their high alkalinity." 
In a study by Matsunaga (1988) using 5% aqueous solutions of ammonium 
thioglycolate, three out of seven beauticians showed a positive response for contact 
dermatitis. 
After exposure of rabbits' skin to a daily application of 0.6 N ammonium 
thioglycolate (PH 9.3) for 20 days, 6.5 mVkg/day was determined to be innocuous 
(Kauder 1983). 
Sodium thioglycolate was rated non-carcinogenic as a result of a study in which 
1 % and 2 % solutions in acetone were applied to the shaved skin of mice and rabbits 
twice weeldy during the lifetime of the animals (Kauder 1983). 
Upon intraperitoneal injection of thioglycolic acid ethyl ester in the rat, the LDso 
was reported as 176 mg/kg. No toxicity effects were noted. With oral administration 
to the rat, the LDso was reported as 178 mg/kg. No toxicity effects were noted (Schmidt 
1974). Intraperitoneal injection of sodium thioglycolate in the rat indicated an LDso of 
126 mg/kg. Somnolence and dyspnea were noted. An LDLO of 500 mg/kg was observed 
with intravenous injection in dogs. Tremors, g.i. hypermotility, diarrhea, nausea and 
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vomiting occurred. Oral administration to the mouse gave an LDso of 504 mg/kg. 
Somnolence and some convulsions were observed (Freeman 1956). Intravenous injection 
to the mouse gave an LD50 of 422 mg/kg. No toxic effects were noted (Ito 1985). 
2. Cysteamine 
Cysteamine has been shown to have radioprotective capability by protecting, 
transforming, and scavenging -OH radicals (Held 1984). Cysteamine also decreases 
acetaminophen hepatotoxicity by decreasing the cytochrome P-450 dependent formation 
of the toxic acetaminophen metabolite mercatopurate (Miller 1986). Dunsford and 
co-workers (1984) evaluated cysteamine as a potential inhibitor of carcinogenesis. The 
data suggested possible tissue-specific anticarcinogenic properties. 
Cysteamine subcutaneously is widely used in rodents to induce duodenal ulcers 
through a systemic mechanism of gastrin release (Man 1984, McIntosh 1984). Trier and 
co-workers (1987) and Mizui and co-workers (1987) independently indicated that 
cysteamine has a gastroprotection effect of ethanol induced gastric mucosal damage. 
Voss (1958), in an attempt to sensitize guinea pig skin, had 0% sensitized out of five 
animals tested. 
Upon intravenous injection of cysteamine in the rabbit, the LDso was reported as 
150 mg/kg. No toxicity effects were noted. With intraperitoneal injection in the rabbit, 
the LD50 was reported to be 232 mg/kg. Here again, no toxicity effects were noted 
(Beccari 1955). 
HR# 3893-R M.U.S.C. 
3. Mercaptoethanol 
White and co-workers (1973) reported on the toxicity of mercaptoethanol tested 
for primary irritation on abraded and unabraded rabbit skin. Undiluted 
2-mercaptoethanol was moderately irritating on topical application to both abraded and 
normal skin of rabbits. Although the irritation to normal skin was transient, that to 
abraded areas was quite long lasting. Furthermore, primary reactions of a similar 
magnitude to ethanol healed much more quickly than those to 2-mercaptoethanol. 
Dilutions of 1:5 and 1: 10 of 2-mercaptoethanol produced a moderate, transitory irritation 
in abraded skin and only a very slight reaction in normal skin. Edema was of little 
significance at any concentration level below 100%. In summary, he states that 
2-mercaptoethanol was only slightly irritating upon topical application to normal skin but 
elicited quite severe reactions on exposure to abraded and intracutaneous tissues. 
Upon oral administration to the mouse, the LD.so was reported as 200 mg/kg. 
Behavioral changes were noted and consisted mainly of excitability. Respiratory 
depression was also indicated. With oral administration to the rat, the LD.so was reported 
as 244 mg/kg. Respiratory depression was observed here also (pugaeva 1971). 
4. Dimercaprol 
Dimercaprol is marketed in the u.s. and abroad as an injectable indicated for 
arsenic, gold, and mercury poisoning. On the skin of man or animals, dimercaprol 
causes localized erythema and edema but no necrosis or blister formation (Waters 1945). 
Dilutions still therapeutically active, on the order of 5-10%, completely prevent 
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skin lesions caused by lewisite and other vesicant arsenicals. Sulzberger and co-workers 
(1946) have reported sensitization in humans. 
Intramuscular injection in the human yielded a TDLO of 3 mg/kg, Hemorrhaging 
and dermatitis were also noted (Waters 1945), Upon intramuscular injection in the 
mouse, the LDso was reported to be 113 mg/kg. No toxic effects were evident 
(Kuschinsky 1954), After intramuscular injection in the rat, the LDso was determined 
to be 87 mg/kg. No toxicity effects were noted. (Danie11947). Upon intraperitoneal 
injection in the rat, the LDso was found to be 105 mg/kg. No toxic effects were 
indicated (Cheymo11947). An intravenous injection to the mouse yielded an LDso of 56 
mg/kg, No toxic effects were observed (Stratford 1984). Intravenous injection in the 
rabbit yielded an LD50 of 50 mg/kg. No toxicity effects were noted. (Daniel 1947). 
Upon intraperitoneal injection in the rabbit, the LDso was reported as 40 mg/kg. The 
toxicity effect observed was an increase in blood pressure. A subcutaneous injection in 
the rabbit yielded an LDso of 2 gm/kg (Cheymo11947). 
5. Dithiothreitol 
Dithiothreitol has been used to reverse acetaminophen hepatotoxicity (Tee 1986), 
cadmium-induced hepatotoxicity (Stacey 1986), and partial reversal of mercury-induced 
renal toxicity (Klonne 1985). In a monolayer of Chinese hamster cells low 
concentrations (0.4 and 1,0 mM) caused cell killing, but higher concentrations (above 
2mM) did not. 
In a paper by Lightowler and Lightowler (1971) the mucolytic activity of 
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dithiothreitol, L-Cysteine, and N-Acetylcysteine was studied. The latter is currently 
marketed as Mucomys~ by Mead-Johnson, Pharmaceuticals for bronchopulmonary 
diseases and complications. In treating human respiratory mucus in vitro, dithiothreitol 
was shown to be a superior agent for the specific and total reduction in viscosity. A 
second objective of the study was to assess, in a suitable animal model, the irritation that 
may be caused by the topical application of the stated compounds to the tracheal mucosa 
surface. Histopathological examination showed minor or moderate epithelial losses with 
fibrinous and polymorph acute inflammatory infIltration with varying degrees of 
hemorrhage with all three compounds. The polymorph infiltration was restricted to the 
submucosal layer immediately deep to the epithelium without loss of epithelial cells. 
Reactions specific to dithiothreitol were dilation of mucosal gland ducts with polymorph 
exudate into the dilated glands. These reactions were limited to two rats using 0.01 ml 
of 0.1 M and 0.5 M concentrations. In summary, the authors concluded • dithiothreitol 
was the most effective mucolytic and had the most favourable minimum effective dose to 
minimum irritant ratio and is the drug of choice" . 
Kobayasi and co-workers (1977), in a study of the degradation effects on dermal 
fibrillar structures of, among other compounds, dithioerythritol (an isomer of 
dithiothreitol), found that this compound did not affect collagen fibers at all, transformed 
elastic fibrils into smooth-surfaced, dense, beaded strings, and at the dermo-epidermal 
junction the anchoring fibrils were unchanged. It should be noted the human skin punch 
biopsies were incubated in dithioerythritol solution for six hours as opposed to a one time 
application to the outermost stratum corneum only as described in this study. 
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In a study by Harber and co-workers (1972) of photo protection against JKlrphyrin 
photosensitization using dithiothreitol, one hundred mice were injected intra peritoneally 
with 80 mg/kg body weight of dithiothreitol in a 5.5% glycerol solution. This group 
showed a 75% reduction in mortality (p<O.03). No lethal effects were observed in 
animals treated with dithiothreitol in the above concentrations without 400 nm of 
radiation. 
Upon intramuscular injection of dithiothreitol in the mouse, the LDso was reported 
as 108 mg/kg. Behavioral changes were noted (Weatherall 1949). The LDso for an 
intraperitoneal injection to the mouse was reported as 154 mg/kg. No toxicity effects 
were noted (Shinoda 1974). 
6. Monothioglycerol 
Monothioglycerol has been used in veterinary medicine to promote wound healing 
(Windholz 1976). 
Subcutaneous injections into hamsters at a dose of 25 mg/kg body weight twice 
daily for 5 weeks deprived 4 out of 5 males of their fertility. This was due to a sperm 
toxic action rather than a lack of spermatogenesis (Das 1978). 
Application of pure monothioglycerol to the clipped skin of rabbit indicates that 
20 to 25 times as much is required to produce a systemic effect as when given 
intravenously. In both the cat and the rat monothioglyceroI is one-sixth to one-fourth as 
toxic as dimercaprol. Repeated topical administration (7.5 % aqueous solution six days 
a week for two months) produced mild thyroid hyperplasia, but this was not seen when 
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given intraperitoneally. No gross abnormalities were seen in major organs upon autopsy 
(Kensler 1949). 
Upon intraperitoneal injection of monothioglycerol in the mouse, the LDso was 
reported to be 340 mg/kg. The LDso for intraperitoneal injection in the rat was 
determined as 390 mg/kg. Lacrimation and behavioral changes were observed when 
given intraperitoneally in the mouse and rat and intravenously in the cat and rabbit 
(Freeman 1956). 
E. Consultants/Collaborators 
No consultants/collaborators are needed for this study. The C.V. of the principle 
investigator is included in the appendix. 
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G. Facilities Available 
A research laboratory (QE-319) will be used to conduct the study. This lab is 
located in the Quadrangle building in the Dept. of Pharmaceutical Sciences ofM.U,S.C. 
Clinical resources, office space, secretarial and clerical assistance, and emergency 
equipment and resources normally available to the department are available for this 
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